GVR Report cover Molecular Diagnostics Market Size, Share & Trends Report

Molecular Diagnostics Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents), By Test Location (Point of Care, Self-Test), By Technology, By Application, By Region, And Segment Forecasts, 2025 - 2030

  • Report ID: 978-1-68038-086-6
  • Number of Report Pages: 269
  • Format: PDF, Horizon Databook
  • Historical Range: 2018 - 2023
  • Forecast Period: 2025 - 2030 
  • Industry: Healthcare

Molecular Diagnostics Market Size & Trends

The global molecular diagnostics market size was estimated at USD 25.75 billion in 2024 and is projected to grow at a CAGR of 3.97% from 2025 to 2030. Technological advancements, an increasing elderly demographic, and a rising demand for accurate and efficient genetic testing solutions are key factors driving market growth. Furthermore, the rising popularity of Point-of-Care (POC) testing is fueled by the growing need for self-diagnostic tools and increased patient awareness of the advantages of quicker diagnostic results. This trend is motivating companies to innovate and launch new testing products. For instance, in February 2023, Huwel Lifesciences developed a portable RT PCR machine capable of testing various viruses, including respiratory diseases and STDs, in about 30 minutes. Designed for use in clinics and corporate settings, it offers high accuracy similar to traditional PCR tests without needing specialized training or environments.

Molecular Diagnostics Market Size, By Product, 2018 - 2030 (USD Billion)

The increase in the global elderly population is a major factor driving the market growth. According to the World Population Prospects 2022, the global elderly population aged 65 years and above is expected to increase from approximately 10% in 2022 to around 16% in 2050. The older population is more vulnerable to chronic and infectious diseases, such as cancer, cardiovascular ailments, diabetes, and neurodegenerative disorders, which create a demand for advanced diagnostic technologies. Molecular diagnostics, recognized for their accuracy and capability to identify diseases at an early stage, are becoming increasingly essential for addressing the healthcare requirements of the aging demographic.

As the demand for point-of-care testing (POCT) continues to rise, various trends are transforming the market and promoting its integration within the molecular diagnostics field. Recently, there has been a notable shift towards increased specialization in clinical departments, with tailored designs emerging to address specific diagnostic requirements across a range of medical applications. This development aligns with the rising trend towards healthcare decentralization, where larger diagnostic devices become available in smaller facilities, and POCT products are designed for enhanced precision, speed, and cost-effectiveness.

Market participants are significantly involved in creating innovative point-of-care (POC) testing products to grab emerging market opportunities. For instance, in November 2024, an innovative pilot program for self-collected HPV screening was initiated in Texas, aimed at enhancing access to cervical cancer screening in underserved communities. This initiative, conducted at Su Clinica Federally Qualified Health Center (FQHC) in partnership with The University of Texas MD Anderson Cancer Center, is designed to assess the effectiveness of self-collection testing in practical healthcare environments. By employing the FDA-approved BD Onclarity HPV Assay, the study tackles significant obstacles to cervical cancer screening, such as geographic and socioeconomic disparities, while exploring effective strategies to enhance healthcare delivery. In addition, the program promotes the adoption of POC testing by showcasing its feasibility and effectiveness in addressing public health issues. By validating the use of self-collection methods in resource-limited settings, this initiative aims to increase confidence among healthcare providers and policymakers regarding the implementation of similar technologies for wider applications.

Market Concentration & Characteristics

The market growth stage is low, and the pace is accelerating. The molecular diagnostics industry is characterized by a low degree of growth due to the rising geriatric population base, increasing demand for point-of-care testing, increasing R&D funding, and the increasing introduction of technologically advanced products.

The molecular diagnostics industry is characterized by a high degree of innovation owing to increasing efforts by market players to develop innovative solutions to increase their market presence. For instance, in March 2023, Sysmex Life Science launched the Sentifitr 800 analyzer, a fully automated and high-throughput device designed for fecal immunochemical testing. This new product enhances diagnostic efficiency, supporting laboratories in delivering rapid and accurate results while expanding Sysmex's product offerings in the life sciences sector.

Molecular Diagnostics Industry Dynamics

The regulatory landscape significantly influences the molecular diagnostics industry, presenting both challenges and opportunities, as a streamlined regulatory framework can enhance product approval processes, enhance innovation, and ensure high-quality testing. However, stringent regulations may delay product development and increase costs, limiting access to advanced diagnostics. For instance, according to an article published by Yale School of Medicine in February 2024, Yale experts are concerned over the FDA's proposed ruling to regulate laboratory-developed tests (LDTs), fearing it may limit access to crucial diagnostics, particularly for rare diseases. The ruling could hinder rapid responses to pandemics and increase costs, ultimately compromising patient care and safety despite intentions to enhance regulation.

The molecular diagnostics industry is witnessing significant mergers and acquisitions (M&A) activity as strategic M&A activities allow companies to enhance their product portfolios and expand their market presence, positioning themselves competitively in the market. For instance, in January 2023, Thermo Fisher Scientific completed its acquisition of The Binding Site Group, enhancing its specialty diagnostics segment, particularly in oncology testing for multiple myeloma. This acquisition is expected to improve patient outcomes through advanced diagnostic technologies.

The threat of substitutes in the molecular diagnostics industry is significant due to the presence of alternative testing methods, such as immunoassays and traditional microbiology tests. However, this threat is not high because molecular diagnostics offer enhanced accuracy and specificity, which are crucial for early disease detection and personalized medicine. In addition, advancements in technology and the growing demand for point-of-care testing further enhance the demand for molecular diagnostics over substitutes.

The molecular diagnostics industry has a significant end-user concentration, primarily among hospitals, diagnostic laboratories, research institutions, and others. Hospitals are among the key players, benefiting from increased patient hospitalizations and government support for advanced diagnostic technologies. This concentration highlights the crucial role these facilities play in the adoption and utilization of molecular diagnostics.

Product Insights

The reagents segment led the market with the largest revenue share of 65.44% in 2024, and is expected to witness at the fastest CAGR of 4.18% over the forecast period. This can be attributed to the increasing demand for accurate and efficient diagnostic tools across various healthcare sectors, including oncology, infectious diseases, and genetic disorders. Reagents, which include enzymes, probes, primers, and buffers, are critical components in molecular diagnostic tests such as PCR, NGS, and digital PCR. Moreover, the continuous innovation and launch of novel products by key industry players are further contributing to the segment growth. For instance, in April 2023, Cepheid, a subsidiary of Danaher, revealed plans to introduce new tests for infectious diseases, including respiratory illnesses and tuberculosis. These advancements are expected to improve efficiency, standardize results, and reduce costs, supporting the overall market expansion.

The instruments segment is expected to witness at a significant CAGR during the forecast period, owing to the increasing demand for early disease detection, particularly in oncology, infectious diseases, and genetic disorders. Technologies such as PCR, NGS, and microarrays are crucial for diagnosing conditions such as cancer, HIV, and genetic diseases. With the global cancer burden expected to rise to 30 million new cases by 2040 and cancer diagnoses in the Americas predicted to reach 6.23 million, a 57% increase, the need for accurate diagnostics is also anticipated to increase significantly.

Test Location Insights

Based on test location, the central laboratories segment led the market with the largest revenue share of 78.8% in 2024, owing to advancements in laboratory technology, including automation and integration, which significantly enhance testing efficiency and throughput. Central laboratories are capable of managing a large volume of tests, ensuring faster and more precise diagnoses, and their role in disease detection, monitoring, and personalized medicine continues to drive the market forward. Moreover, key market players are continuously developing and offering laboratory-based molecular diagnostic solutions. For instance, in September 2024, QIAGEN released the QIAcuityDx Digital PCR System, a significant innovation in molecular diagnostics. This system, designed for clinical testing in oncology, provides precise quantification of DNA and RNA, supporting applications such as cancer monitoring through liquid biopsies. With integrated partitioning, thermocycling, and imaging, the QIAcuityDx system reduces laboratory space and costs while offering increased throughput, precision, and faster processing times.

The self-test or OTC segment is expected to witness at the fastest CAGR over the forecast period. This can be attributed to the increasing consumer demand for at-home health monitoring solutions. This segment enables individuals to perform diagnostic tests in the comfort of their homes without the need for clinical intervention. The rising focus on convenience, privacy, and cost-effective healthcare solutions has accelerated the adoption of self-test kits for conditions such as infectious diseases, genetic testing, and wellness monitoring. Technological advancements in test accuracy and ease of use are further enhancing the segment's growth, positioning it as a key player in personalized healthcare.

Technology Insights

Based on technology, the PCR segment led the market with the largest revenue share of 68.0% in 2024. PCR technologies encompass several methods, such as quantitative PCR, reverse transcription PCR, inverse PCR, and multiplex PCR, with multiplex PCR emerging as a preferred method for its ability to detect multiple targets simultaneously. Real-time PCR has become particularly important for cancer marker analysis, contributing to the growing use of high-throughput PCR techniques for cancer detection. The development of digital PCR systems has further fueled segment growth. For instance, Thermo Fisher Scientific's 2023 release of the QuantStudio Absolute Q AutoRun dPCR Suite automates lab processes, improving efficiency and reducing costs, while Roche’s Digital LightCycler System launched significantly advanced cancer detection methods in 2022.

The ISH segment is expected to witness at the fastest CAGR during the forecast period, owing to recent launches, including RNAscope ISH probes for B-cell lymphoma and HPV detection, enhance diagnostic precision, support clinical applications, and cater to the rising demand for advanced cancer diagnostic tools. For instance, in May 2023, Bio-Techne launched Kappa and Lambda RNAscope ISH Probes as ASRs for detecting immunoglobulin kappa and lambda light chain mRNA in B-cells. These probes aid in assessing B-cell clonality, which is crucial for diagnosing B-cell lymphomas. Unlike traditional methods, RNAscope probes offer high sensitivity, especially for FFPE tissues. The new probes support laboratory-developed tests (LDTs) and are compliant with GMP standards, enhancing accuracy in clinical diagnostics and research.

Application Insights

Based on application, the infectious disease segment led the market with the largest revenue share of 63.1% in 2024. This can be attributed to the rising demand for rapid and accurate detection of pathogens. Molecular diagnostic techniques, such as polymerase chain reaction (PCR) and next-generation sequencing, have revolutionized the identification of infectious agents, enabling healthcare providers to diagnose conditions such as tuberculosis, HIV, and various viral infections more efficiently than traditional culture methods. Moreover, key market players contribute to the growth of the infectious disease by developing innovative, rapid, and accurate diagnostic technologies. For instance, in May 2022, BD launched the fully automated BD COR MX system in the U.S., which processes up to 1,700 specimens with minimal staff interaction. The system first detects three common STIs: Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis. This system improves efficiency and enables labs to handle higher volumes of tests, particularly for women’s health and STI testing.

Molecular Diagnostics Market Share, By Application, 2024 (%)

The oncology segment is expected to witness at a significant CAGR during the forecast period, owing to the increasing demand for early detection, personalized treatment, and monitoring of cancer therapies. Molecular diagnostic technologies are essential for identifying genetic mutations, cancer biomarkers, and tumor-specific variations that guide treatment decisions. Moreover, the increasing global prevalence of cancer is a key factor driving segment growth. As per American Cancer Society estimates, in 2022, around 1,918,030 new cases of cancer were reported in the U.S., and around 609,360 individuals in the U.S. died due to cancer. Hence, oncology holds one of the largest shares in the applications segment.

Regional Insights

North America dominated the molecular diagnostic market with the largest revenue share of 40.95% in 2024, owing to the growing adoption of molecular diagnostics, which are valued for their superior accuracy, sensitivity, and specificity. The rising demand for genetic testing, particularly for personalized healthcare in conditions such as diabetes and cancer, is anticipated to fuel market expansion. Moreover, the increasing regulatory support for advanced solutions further contributes to market growth. For instance, in 2022, Myriad Genetics, Inc. received U.S. FDA approval for its BRACAnalysis CDx test as a companion diagnostic. This test identifies patients with germline BRCA mutations (gRBCAm) in HER2-negative, high-risk early-stage breast cancer who may benefit from treatment with Lynparza (olaparib).

Molecular Diagnostics Market Trends, by Region, 2025 - 2030

U.S. Molecular Diagnostics Market Trends

The molecular diagnostics market in the U.S. is driven by the presence of key market players, favorable reimbursement policies, developed R&D infrastructure, and the rising prevalence of various health conditions in the country. For instance, according to the American Cancer Society, over 2 million new cancer cases are projected to be diagnosed in the U.S. in 2024. This figure excludes basal and squamous cell skin cancers, which are not mandatory for reporting to cancer registries, as well as noninvasive carcinoma in situ, with the exception of urinary bladder cases. These factors are expected to contribute to the market growth in the U.S.

The Canada molecular diagnostics market is expected to witness at a significant CAGR over the forecast period. The rising number of cancer cases highlights an increasing need for advanced molecular diagnostics to enable early detection and personalized treatment are driving market growth. According to the Canadian Cancer Society, an estimated 247,100 Canadians are expected to be diagnosed with cancer in 2024, up from 239,100 new cases in 2023. This increase is largely attributed to Canada's growing and aging population. In addition, cancer-related deaths are projected to rise from 86,700 in 2023 to 88,100 in 2024. Such a rise in the prevalence of cancer in the country is expected to fuel the market growth in the country.

Europe Molecular Diagnostics Market Trends

The molecular diagnostics market in Europe is anticipated to witness at a significant growth, driven by the increasing prevalence of genetic and cardiovascular disorders and growing investments in proteomics & genomic research initiatives. According to WHO data from 2024, cardiovascular diseases (CVDs) are the leading cause of disability and premature death in the European Region, responsible for over 42.5% of all deaths annually. This equates to approximately 10,000 deaths per day. Thus, the rising CVD population is expected to boost demand for molecular tests during the forecast period.

The UK molecular diagnostics market is experiencing significant growth, driven by the presence of developed healthcare infrastructure, high disposable income, and growing awareness about the benefits of early diagnosis. In April 2024, the rollout of community diagnostic centers (CDCs) across England is set to address long waiting lists, provide better value for taxpayers, and contribute to decarbonizing the NHS. Such efforts to enhance the efficiency of the country’s healthcare sector and services are further expected to fuel the market growth over the forecast period.

The molecular diagnostics market in Germany is driven by the increasing demand for faster, more accurate diagnostic solutions across various therapeutic areas, particularly infectious diseases, oncology, and genetic disorders. Moreover, the country’s growing geriatric population base further contributes to market growth. According to the UN’s population data, one in every 20 people in Germany is over 80 years old, which is expected to increase to one in every six individuals by 2050. This population has a higher risk of chronic diseases, such as diabetes, cardiovascular diseases, and neurovascular disorders, due to the onset of senescence & decreased immunity levels.

Asia Pacific Molecular Diagnostics Market Trends

The molecular diagnostics market in the Asia Pacific region is driven by a high burden of various conditions such as TB, drug-resistant TB, multi-drug-resistant (MDR-TB), and rifampicin-resistant (RR-TB) TB cases. For instance, according to the WHO Global TB Report 2023, the WHO South-East Asia (SEA) Region, which was home to approximately one-fourth of the global population, carries a significant burden of tuberculosis (TB), accounting for over 45% of the annual TB incidence. In 2022, more than 4.8 million people in this region fell ill with TB, and over 600,000 people died from the disease, excluding HIV-related TB mortality. This represents more than half of all global TB-related deaths. Moreover, the developing healthcare infrastructure and growing geriatric population further contribute to this growth in the region.

The China molecular diagnostics market is anticipated to witness at a significant CAGR during the forecast period, driven by the rising geriatric population, increasing R&D initiatives, and increasing demand for effective diagnostics solutions in the country. For instance, in December 2020, Genetron Health announced the launch of a novel cancer screening kit worth USD 765, facilitating the assessment of risk for eight types of cancer. Similarly, AnchorDx received funding of USD 40 million to develop screening and diagnostic tests. Such initiatives are expected to fuel the market growth in the country.

Latin America Molecular Diagnostics Market Trends

The molecular diagnostics market in Latin America is experiencing significant growth, primarily driven by the rising R&D initiatives in the country, the rising prevalence of chronic diseases, and the growing geriatric population. Furthermore, key players and organizations are adopting strategic initiatives to increase their regional presence, fueling market growth during the forecast period. For instance, In September 2023, the Pan American Health Organization (PAHO) partnered with FIND to enhance the availability of essential diagnostic tests across Latin America and the Caribbean.

Middle East and Africa Molecular Diagnostics Market Trends

The molecular diagnostics market in the Middle East and Africa (MEA) is experiencing significant growth, driven by the increasing prevalence of chronic conditions, such as cancer, cardiovascular diseases, and other diseases is expected to accelerate market growth. According to WHO estimates, in 2020, cancer incidence in the Middle East is expected to double by 2030. Around 9 out of 22, countries in the MEA did not have optimal operational facilities to deal with cancer. Economic development and the presence of high unmet healthcare needs-witnessed in emerging markets such as South Africa are also contributing to the market growth.

The Saudi Arabia molecular diagnostics market is experiencing significant growth, driven by various factors, such as the rising prevalence of non-communicable diseases, including cardiovascular diseases (CVDs) and diabetes. According to ScienceDirect, the prevalence of CVDs is estimated to reach 479,500 by 2035. Similarly, according to the International Diabetes Atlas, in 2021, over 4.27 million people in the country had diabetes. In 2023, the nation is anticipated to witness a diagnosis of over 31,000 new cancer cases. Chronic diseases need constant support from diagnostics and immunoassays to make treatment possible. Hence, the growing prevalence is expected to create growth opportunities. 

Key Molecular Diagnostics Company Insights

Key market players are adopting various strategic initiatives such as launches, partnerships, collaborations, mergers & acquisitions, approvals, expansion, and others to increase their presence in the global molecular diagnostics market. These advancements in the molecular diagnostics industry are anticipated to boost market growth over the forecast period.

Key Molecular Diagnostics Companies:

The following are the leading companies in the molecular diagnostics market. These companies collectively hold the largest market share and dictate industry trends.

View a comprehensive list of companies in the Molecular Diagnostics Market

Recent Developments

  • In August 2024, Sysmex Corporation expanded its strategic alliance with QIAGEN to enhance genetic testing, focusing on research, development, production, clinical trials, and global sales marketing.

  • In January 2023, QIAGEN announced the launch of its EZ2 Connect MDx platform, aimed at enhancing its automation capabilities for sample processing. The platform will be compatible with dPCR, PCR, and other downstream applications.

  • In February 2023, BD received FDA Emergency Use Authorization for a molecular diagnostic test that detects COVID-19, influenza A/B, and RSV. The test, for use with the BD MAX System, provides results in under two hours from a single nasal or nasopharyngeal swab, improving testing efficiency during respiratory virus seasons.

  • In April 2023, Quest Diagnostics Incorporated acquired the MRD Platform of Haystack Oncology. It is an early-stage business specializing in testing for Minimal Residual Disease (MRD). 

Molecular Diagnostics Market Report Scope

Report Attribute

Details

Market size value in 2025

USD 27.24 billion

Revenue forecast in 2030

USD 33.08 billion

Growth rate

CAGR of 3.97% from 2025 to 2030

Base year for estimation

2024

Historical data

2018 - 2023

Forecast period

2025 - 2030

Quantitative units

Revenue in USD million/billion, and CAGR from 2025 to 2030

Report coverage

Revenue, competitive landscape, growth factors, and trends

Segments covered

product, test location, technology, application, region

Regional scope

North America; Europe; Asia Pacific; Latin America; & MEA

Country scope

U.S.; Canada; Mexico; UK; Germany; France; Spain; Italy; Belgium; Switzerland; Netherlands; Poland; Austria; Denmark; Sweden; Turkey; Norway; China; India; Australia; New Zealand; Sri Lanka; Malaysia; Thailand; Vietnam; Singapore; Brazil; Colombia; Chile; Peru; Argentina; South Africa; Saudi Arabia; Jordan; UAE; Qatar; Kuwait; Egypt

Key companies profiled

BD; BIOMÉRIEUX; Bio-Rad Laboratories, Inc.; Abbott; Agilent Technologies, Inc.; Danaher; Hologic Inc. (Gen Probe); Illumina, Inc.; Grifols; QIAGEN; F. Hoffmann-La Roche, Ltd.; Siemens Healthineers AG; Sysmex Corporation

Customization scope

Free report customization (equivalent up to 8 analysts' working days) with purchase. Addition or alteration to country, regional & segment scope

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Global Molecular Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global molecular diagnostics market report based on the product, test location, technology, application, and region:

  • Product Outlook (Revenue, USD Million, 2018 - 2030)

    • Instruments

    • Regards

    • Others

  • Test Location Outlook (Revenue, USD Million, 2018 - 2030)

    • Point of care

    • Self-test or OTC

    • Central laboratories

  • Technology Outlook (Revenue, USD Million, 2018 - 2030)

    • Polymerase chain reaction (PCR)

      • PCR, by Procedure

        • Nucleic Acid Extraction

        • Others

      • PCR, by Type

        • Multiplex PCR

        • Other PCR

      • PCR, by Product

        • Instruments

        • Reagents

        • Others

    • In Situ Hybridization (ISH)

      • Instruments

      • Reagents

      • Others

    • Isothermal Nucleic Acid Amplification Technology (INAAT)

      • Instruments

      • Reagents

      • Others

    • Chips and Microarrays

      • Instruments

      • Reagents

      • Others

    • Mass Spectrometry

      • Instruments

      • Reagents

      • Others

    • Transcription Mediated Amplification (TMA)

      • Instruments

      • Reagents

      • Others

    • Others

      • Instruments

      • Reagents

      • Others

  • Application Outlook (Revenue, USD Million, 2018 - 2030)

    • Oncology

      • Breast Cancer

      • Prostate Cancer

      • Colorectal Cancer

      • Cervical

      • Kidney

      • Liver

      • Blood

      • Lung

      • Other

    • Pharmacogenomics

    • Infectious disease

      • MRSA

      • Clostridium difficile

      • Vancomycin-resistant enterococci

      • Carbapenem-resistant bacteria testing

      • Flu

      • Respiratory syncytial virus (RSV)

      • Candida

      • Tuberculosis and drug-resistant TB

      • Meningitis

      • Gastro-intestinal panel testing

      • Chlamydia

      • Gonorrhea

      • HIV

      • Hepatitis C

      • Hepatitis B

      • Other Infectious Diseases

    • Genetic testing

      • Newborn screening

      • Predictive and presymptomatic testing

      • Others

    • Neurological disease

    • Cardiovascular disease

    • Microbiology

    • Others

  • Regional Outlook (Revenue, USD Million, 2018 - 2030)

    • North America

      • U.S.

      • Canada

      • Mexico

    • Europe

      • Germany

      • UK

      • France

      • Italy

      • Spain

      • Sweden

      • Denmark

      • Norway

    • Asia Pacific

      • China

      • Japan

      • India

      • South Korea

      • Australia

      • Thailand

    • Latin America

      • Brazil

      • Argentina

    • Middle East and Africa (MEA)

      • South Africa

      • Saudi Arabia

      • UAE

      • Kuwait

Frequently Asked Questions About This Report

Table of Contents

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation and Scope
                    1.2. Segment Definitions
                        1.2.1. Application
                        1.2.2. End Use
                        1.2.3. Regional Scope
                        1.2.4. Estimates and forecasts timeline
                    1.3. Research Methodology
                    1.4. Information Procurement
                        1.4.1. Purchased database
                        1.4.2. GVR’s internal database
                        1.4.3. Secondary sources
                        1.4.4. Primary research
                        1.4.5. Details of primary research
                    1.5. Information or Data Analysis
                        1.5.1. Data analysis models
                    1.6. Market Formulation & Validation
                    1.7. Model Details
                        1.7.1. Commodity flow analysis (Model 1)
                        1.7.2. Approach 1: Commodity flow approach
                        1.7.3. Volume price analysis (Model 2)
                        1.7.4. Approach 2: Volume price analysis
                    1.8. List of Secondary Sources
                    1.9. List of Primary Sources
                    1.10. Objectives
Chapter 2. Executive Summary
                    2.1. Market Outlook
                    2.2. Segment Outlook
                    2.3. Regional outlook
                    2.4. Competitive Insights
Chapter 3. Molecular Diagnostics Variables, Trends & Scope
                    3.1. Market Lineage Outlook
                        3.1.1. Parent Market Outlook
                        3.1.2. Related/ancillary market outlook
                    3.2. Market Dynamics
                        3.2.1. Market Driver Analysis
                            3.2.1.1. Increase in geriatric population
                            3.2.1.2. Introduction of technologically advanced products
                            3.2.1.3. Increase in demand for point-of-care Testing
                            3.2.1.4. Growing prevalence of target diseases
                            3.2.1.5. Increasing external funding for R&D
                            3.2.1.6. Outbreak of COVID-19
                        3.2.2. Market Restraint Analysis
                            3.2.2.1. Presence of ambiguous regulatory framework
                            3.2.2.2. High prices of molecular diagnostics tests
                    3.3. Molecular Diagnostics Analysis Tools
                        3.3.1. Industry Analysis - Porter’s
                            3.3.1.1. Bargaining power of suppliers
                            3.3.1.2. Bargaining power of buyers
                            3.3.1.3. Threat of substitutes
                            3.3.1.4. Threat of new entrants
                            3.3.1.5. Competitive rivalry
                        3.3.2. PESTEL Analysis
                            3.3.2.1. Political landscape
                            3.3.2.2. Economic landscape
                            3.3.2.3. Social landscape
                            3.3.2.4. Technological landscape
                            3.3.2.5. Environmental landscape
                            3.3.2.6. Legal landscape
Chapter 4. Molecular Diagnostics Market: Segment Analysis, By Product, 2018 - 2030 (USD Million)
                    4.1. Definition and Scope
                    4.2. Product Market Share Analysis, 2024 & 2030
                    4.3. Molecular Diagnostics Market, by Product, 2018 to 2030
                    4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030
                        4.4.1. Instruments
                            4.4.1.1. Instruments market, 2018 - 2030 (USD Million)
                        4.4.2. Reagents
                            4.4.2.1. Reagents market, 2018 - 2030 (USD Million)
                        4.4.3. Others
                            4.4.3.1. Others market, 2018 - 2030 (USD Million)
Chapter 5. Molecular Diagnostics Market: Segment Analysis, By Test Location, 2018 - 2030 (USD Million)
                    5.1. Definition and Scope
                    5.2. Test Location Market Share Analysis, 2024 & 2030
                    5.3. Global Molecular Diagnostics Market, by Test Location, 2018 to 2030
                    5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030
                        5.4.1. Point of care
                            5.4.1.1. Point of care market, 2018 - 2030 (USD Million)
                        5.4.2. Self test or OTC
                            5.4.2.1. Self test or OTC market, 2018 - 2030 (USD Million)
                        5.4.3. Central laboratories
                            5.4.3.1. Central laboratories market, 2018 - 2030 (USD Million)
Chapter 6. Molecular Diagnostics Market: Segment Analysis, By Technology, 2018 - 2030 (USD Million)
                    6.1. Definition and Scope
                    6.2. Technology Market Share Analysis, 2024 & 2030
                    6.3. Global Molecular Diagnostics Market, by Technology, 2018 to 2030
                    6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030
                        6.4.1. PCR
                            6.4.1.1. PCR market, 2018 - 2030 (USD Million)
                            6.4.1.2. By procedure
                                6.4.1.2.1. Nucleic acid extraction
                                    6.4.1.2.1.1. Nucleic acid extraction market, 2018 - 2030 (USD Million)
                                6.4.1.2.2. Others
                                    6.4.1.2.2.1. Others market, 2018 - 2030 (USD Million)
                            6.4.1.3. By type
                                6.4.1.3.1. Multiplex
                                    6.4.1.3.1.1. Multiplex market, 2018 - 2030 (USD Million)
                                6.4.1.3.2. Others
                                    6.4.1.3.2.1. Others market, 2018 - 2030 (USD Million)
                            6.4.1.4. By product
                                6.4.1.4.1. Instruments
                                    6.4.1.4.1.1. Instruments market, 2018 - 2030 (USD Million)
                                6.4.1.4.2. Reagents
                                    6.4.1.4.2.1. Reagents market, 2018 - 2030 (USD Million)
                                6.4.1.4.3. Others
                                    6.4.1.4.3.1. Others market, 2018 - 2030 (USD Million)
                        6.4.2. ISH
                            6.4.2.1. ISH market, 2018 - 2030 (USD Million)
                            6.4.2.2. Instruments
                                6.4.2.2.1. Instruments market, 2018 - 2030 (USD Million)
                            6.4.2.3. Reagents
                                6.4.2.3.1. Reagents market, 2018 - 2030 (USD Million)
                            6.4.2.4. Others
                                6.4.2.4.1. Others market, 2018 - 2030 (USD Million)
                        6.4.3. INAAT
                            6.4.3.1. INAAT market, 2018 - 2030 (USD Million)
                            6.4.3.2. Instruments
                                6.4.3.2.1. Instruments market, 2018 - 2030 (USD Million)
                            6.4.3.3. Reagents
                                6.4.3.3.1. Reagents market, 2018 - 2030 (USD Million)
                            6.4.3.4. Others
                                6.4.3.4.1. Others market, 2018 - 2030 (USD Million)
                        6.4.4. Chips and microarrays
                            6.4.4.1. Chips and microarrays market, 2018 - 2030 (USD Million)
                            6.4.4.2. Instruments
                                6.4.4.2.1. Instruments market, 2018 - 2030 (USD Million)
                            6.4.4.3. Reagents
                                6.4.4.3.1. Reagents market, 2018 - 2030 (USD Million)
                            6.4.4.4. Others
                                6.4.4.4.1. Others market, 2018 - 2030 (USD Million)
                        6.4.5. Mass spectrometry
                            6.4.5.1. Mass spectrometry market, 2018 - 2030 (USD Million)
                            6.4.5.2. Instruments
                                6.4.5.2.1. Instruments market, 2018 - 2030 (USD Million)
                            6.4.5.3. Reagents
                                6.4.5.3.1. Reagents market, 2018 - 2030 (USD Million)
                            6.4.5.4. Others
                                6.4.5.4.1. Others market, 2018 - 2030 (USD Million)
                        6.4.6. Sequencing
                            6.4.6.1. Sequencing market, 2018 - 2030 (USD Million)
                            6.4.6.2. Instruments
                                6.4.6.2.1. Instruments market, 2018 - 2030 (USD Million)
                            6.4.6.3. Reagents
                                6.4.6.3.1. Reagents market, 2018 - 2030 (USD Million)
                            6.4.6.4. Others
                                6.4.6.4.1. Others market, 2018 - 2030 (USD Million)
                        6.4.7. TMA
                            6.4.7.1. TMA market, 2018 - 2030 (USD Million)
                            6.4.7.2. Instruments
                                6.4.7.2.1. Instruments market, 2018 - 2030 (USD Million)
                            6.4.7.3. Reagents
                                6.4.7.3.1. Reagents market, 2018 - 2030 (USD Million)
                            6.4.7.4. Others
                                6.4.7.4.1. Others market, 2018 - 2030 (USD Million)
                        6.4.8. Others
                            6.4.8.1. Others market, 2018 - 2030 (USD Million)
                            6.4.8.2. Instruments
                                6.4.8.2.1. Instruments market, 2018 - 2030 (USD Million)
                            6.4.8.3. Reagents
                                6.4.8.3.1. Reagents market, 2018 - 2030 (USD Million)
                            6.4.8.4. Others
                                6.4.8.4.1. Others market, 2018 - 2030 (USD Million)
Chapter 7. Molecular Diagnostics Market: Segment Analysis, By Application, 2018 - 2030 (USD Million)
                    7.1. Definition and Scope
                    7.2. Application Market Share Analysis, 2024 & 2030
                    7.3. Global Molecular Diagnostics Market, by Application,2018 to 2030
                    7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030
                        7.4.1. Oncology
                            7.4.1.1. Oncology market, 2018 - 2030 (USD Million)
                            7.4.1.2. Breast cancer
                                7.4.1.2.1. Breast cancer market, 2018 - 2030 (USD Million)
                            7.4.1.3. Prostate cancer
                                7.4.1.3.1. Prostate cancer market, 2018 - 2030 (USD Million)
                            7.4.1.4. Colorectal cancer
                                7.4.1.4.1. Colorectal cancer market, 2018 - 2030 (USD Million)
                            7.4.1.5. Cervical
                                7.4.1.5.1. Cervical market, 2018 - 2030 (USD Million)
                            7.4.1.6. Kidney
                                7.4.1.6.1. Kidney market, 2018 - 2030 (USD Million)
                            7.4.1.7. Liver
                                7.4.1.7.1. Liver market, 2018 - 2030 (USD Million)
                            7.4.1.8. Blood
                                7.4.1.8.1. Blood market, 2018 - 2030 (USD Million)
                            7.4.1.9. Lung
                                7.4.1.9.1. Lung market, 2018 - 2030 (USD Million)
                            7.4.1.10. Other
                                7.4.1.10.1. Other market, 2018 - 2030 (USD Million)
                        7.4.2. Pharmacogenomics
                            7.4.2.1. Pharmacogenomics market, 2018 - 2030 (USD Million)
                        7.4.3. Infectious disease
                            7.4.3.1. Infectious disease market, 2018 - 2030 (USD Million)
                            7.4.3.2. MRSA
                                7.4.3.2.1. MRSA market, 2018 - 2030 (USD Million)
                            7.4.3.3. Clostridium difficile
                                7.4.3.3.1. Clostridium difficile market, 2018 - 2030 (USD Million)
                            7.4.3.4. Vancomycin-resistant enterococci
                                7.4.3.4.1. Vancomycin-resistant enterococci market, 2018 - 2030 (USD Million)
                            7.4.3.5. Carbapenem-resistant bacteria testing
                                7.4.3.5.1. Carbapenem-resistant bacteria testing market, 2018 - 2030 (USD Million)
                            7.4.3.6. Flu
                                7.4.3.6.1. Flu market, 2018 - 2030 (USD Million)
                            7.4.3.7. Respiratory syncytial virus (RSV)
                                7.4.3.7.1. Respiratory syncytial virus (RSV) market, 2018 - 2030 (USD Million)
                            7.4.3.8. Candida
                                7.4.3.8.1. Candida market, 2018 - 2030 (USD Million)
                            7.4.3.9. Tuberculosis and drug-resistant TB
                                7.4.3.9.1. Tuberculosis and drug-resistant TB market, 2018 - 2030 (USD Million)
                            7.4.3.10. Meningitis
                                7.4.3.10.1. Meningitis market, 2018 - 2030 (USD Million)
                            7.4.3.11. Gastro-intestinal panel testing
                                7.4.3.11.1. Gastro-intestinal panel testing market, 2018 - 2030 (USD Million)
                            7.4.3.12. Chlamydia
                                7.4.3.12.1. Chlamydia market, 2018 - 2030 (USD Million)
                            7.4.3.13. Gonorrhea
                                7.4.3.13.1. Gonorrhea market, 2018 - 2030 (USD Million)
                            7.4.3.14. HIV
                                7.4.3.14.1. HIV market, 2018 - 2030 (USD Million)
                            7.4.3.15. Hepatitis C
                                7.4.3.15.1. Hepatitis C market, 2018 - 2030 (USD Million)
                            7.4.3.16. Hepatitis B
                                7.4.3.16.1. Hepatitis B market, 2018 - 2030 (USD Million)
                            7.4.3.17. Other infectious diseases
                                7.4.3.17.1. Other infectious diseases market, 2018 - 2030 (USD Million)
                        7.4.4. Genetic testing
                            7.4.4.1. Genetic testing market, 2018 - 2030 (USD Million)
                            7.4.4.2. Newborn screening
                                7.4.4.2.1. Newborn screening market, 2018 - 2030 (USD Million)
                            7.4.4.3. Predictive and presymptomatic testing
                                7.4.4.3.1. Predictive and presymptomatic testing market, 2018 - 2030 (USD Million)
                            7.4.4.4. Others
                                7.4.4.4.1. Others market, 2018 - 2030 (USD Million)
                        7.4.5. Neurological disease
                            7.4.5.1. Neurological disease market, 2018 - 2030 (USD Million)
                        7.4.6. Cardiovascular disease
                            7.4.6.1. Cardiovascular disease market, 2018 - 2030 (USD Million)
                        7.4.7. Microbiology
                            7.4.7.1. Microbiology market, 2018 - 2030 (USD Million)
                        7.4.8. Others
                            7.4.8.1. Others market, 2018 - 2030 (USD Million)
Chapter 8. Molecular Diagnostics Market: Regional Estimates & Trend Analysis
                    8.1. Regional Dashboard
                    8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
                    8.3. North America
                        8.3.1. U.S.
                            8.3.1.1. Key country dynamics
                            8.3.1.2. Regulatory framework/ reimbursement structure
                            8.3.1.3. Competitive scenario
                            8.3.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
                        8.3.2. Canada
                            8.3.2.1. Key country dynamics
                            8.3.2.2. Regulatory framework/ reimbursement structure
                            8.3.2.3. Competitive scenario
                            8.3.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
                        8.3.3. Mexico
                            8.3.3.1. Key country dynamics
                            8.3.3.2. Regulatory framework/ reimbursement structure
                            8.3.3.3. Competitive scenario
                            8.3.3.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
                    8.4. Europe
                        8.4.1. UK
                            8.4.1.1. Key country dynamics
                            8.4.1.2. Regulatory framework/ reimbursement structure
                            8.4.1.3. Competitive scenario
                            8.4.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
                        8.4.2. Germany
                            8.4.2.1. Key country dynamics
                            8.4.2.2. Regulatory framework/ reimbursement structure
                            8.4.2.3. Competitive scenario
                            8.4.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
                        8.4.3. France
                            8.4.3.1. Key country dynamics
                            8.4.3.2. Regulatory framework/ reimbursement structure
                            8.4.3.3. Competitive scenario
                            8.4.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
                        8.4.4. Spain
                            8.4.4.1. Key country dynamics
                            8.4.4.2. Regulatory framework/ reimbursement structure
                            8.4.4.3. Competitive scenario
                            8.4.4.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
                        8.4.5. Italy
                            8.4.5.1. Key country dynamics
                            8.4.5.2. Regulatory framework/ reimbursement structure
                            8.4.5.3. Competitive scenario
                            8.4.5.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
                        8.4.6. Belgium
                            8.4.6.1. Key country dynamics
                            8.4.6.2. Regulatory framework/ reimbursement structure
                            8.4.6.3. Competitive scenario
                            8.4.6.4. Belgium market estimates and forecasts, 2018 to 2030 (USD Million)
                        8.4.7. Switzerland
                            8.4.7.1. Key country dynamics
                            8.4.7.2. Regulatory framework/ reimbursement structure
                            8.4.7.3. Competitive scenario
                            8.4.7.4. Switzerland market estimates and forecasts, 2018 to 2030 (USD Million)
                        8.4.8. Netherlands
                            8.4.8.1. Key country dynamics
                            8.4.8.2. Regulatory framework/ reimbursement structure
                            8.4.8.3. Competitive scenario
                            8.4.8.4. Netherlands market estimates and forecasts, 2018 to 2030 (USD Million)
                        8.4.9. Poland
                            8.4.9.1. Key country dynamics
                            8.4.9.2. Regulatory framework/ reimbursement structure
                            8.4.9.3. Competitive scenario
                            8.4.9.4. Poland market estimates and forecasts, 2018 to 2030 (USD Million)
                        8.4.10. Austria
                            8.4.10.1. Key country dynamics
                            8.4.10.2. Regulatory framework/ reimbursement structure
                            8.4.10.3. Competitive scenario
                            8.4.10.4. Austria market estimates and forecasts, 2018 to 2030 (USD Million)
                        8.4.11. Denmark
                            8.4.11.1. Key country dynamics
                            8.4.11.2. Regulatory framework/ reimbursement structure
                            8.4.11.3. Competitive scenario
                            8.4.11.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
                        8.4.12. Sweden
                            8.4.12.1. Key country dynamics
                            8.4.12.2. Regulatory framework/ reimbursement structure
                            8.4.12.3. Competitive scenario
                            8.4.12.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
                        8.4.13. Turkey
                            8.4.13.1. Key country dynamics
                            8.4.13.2. Regulatory framework/ reimbursement structure
                            8.4.13.3. Competitive scenario
                            8.4.13.4. Turkey market estimates and forecasts, 2018 to 2030 (USD Million)
                        8.4.14. Norway
                            8.4.14.1. Key country dynamics
                            8.4.14.2. Regulatory framework/ reimbursement structure
                            8.4.14.3. Competitive scenario
                            8.4.14.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
                    8.5. Asia Pacific
                        8.5.1. China
                            8.5.1.1. Key country dynamics
                            8.5.1.2. Regulatory framework/ reimbursement structure
                            8.5.1.3. Competitive scenario
                            8.5.1.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
                        8.5.2. Japan
                            8.5.2.1. Key country dynamics
                            8.5.2.2. Regulatory framework/ reimbursement structure
                            8.5.2.3. Competitive scenario
                            8.5.2.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
                        8.5.3. India
                            8.5.3.1. Key country dynamics
                            8.5.3.2. Regulatory framework/ reimbursement structure
                            8.5.3.3. Competitive scenario
                            8.5.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
                        8.5.4. Australia
                            8.5.4.1. Key country dynamics
                            8.5.4.2. Regulatory framework/ reimbursement structure
                            8.5.4.3. Competitive scenario
                            8.5.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
                        8.5.5. Thailand
                            8.5.5.1. Key country dynamics
                            8.5.5.2. Regulatory framework/ reimbursement structure
                            8.5.5.3. Competitive scenario
                            8.5.5.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
                        8.5.6. Sri Lanka
                            8.5.6.1. Key country dynamics
                            8.5.6.2. Regulatory framework/ reimbursement structure
                            8.5.6.3. Competitive scenario
                            8.5.6.4. Sri Lanka market estimates and forecasts, 2018 to 2030 (USD Million)
                        8.5.7. Malaysia
                            8.5.7.1. Key country dynamics
                            8.5.7.2. Regulatory framework/ reimbursement structure
                            8.5.7.3. Competitive scenario
                            8.5.7.4. Malaysia market estimates and forecasts, 2018 to 2030 (USD Million)
                        8.5.8. Vietnam
                            8.5.8.1. Key country dynamics
                            8.5.8.2. Regulatory framework/ reimbursement structure
                            8.5.8.3. Competitive scenario
                            8.5.8.4. Vietnam market estimates and forecasts, 2018 to 2030 (USD Million)
                        8.5.9. Singapore
                            8.5.9.1. Key country dynamics
                            8.5.9.2. Regulatory framework/ reimbursement structure
                            8.5.9.3. Competitive scenario
                            8.5.9.4. Singapore market estimates and forecasts, 2018 to 2030 (USD Million)
                    8.6. Latin America
                        8.6.1. Brazil
                            8.6.1.1. Key country dynamics
                            8.6.1.2. Regulatory framework/ reimbursement structure
                            8.6.1.3. Competitive scenario
                            8.6.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
                        8.6.2. Colombia
                            8.6.2.1. Key country dynamics
                            8.6.2.2. Regulatory framework/ reimbursement structure
                            8.6.2.3. Competitive scenario
                            8.6.2.4. Colombia market estimates and forecasts, 2018 to 2030 (USD Million)
                        8.6.3. Chile
                            8.6.3.1. Key country dynamics
                            8.6.3.2. Regulatory framework/ reimbursement structure
                            8.6.3.3. Competitive scenario
                            8.6.3.4. Chile market estimates and forecasts, 2018 to 2030 (USD Million)
                        8.6.4. Peru
                            8.6.4.1. Key country dynamics
                            8.6.4.2. Regulatory framework/ reimbursement structure
                            8.6.4.3. Competitive scenario
                            8.6.4.4. Peru market estimates and forecasts, 2018 to 2030 (USD Million)
                        8.6.5. Argentina
                            8.6.5.1. Key country dynamics
                            8.6.5.2. Regulatory framework/ reimbursement structure
                            8.6.5.3. Competitive scenario
                            8.6.5.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
                    8.7. MEA
                        8.7.1. South Africa
                            8.7.1.1. Key country dynamics
                            8.7.1.2. Regulatory framework/ reimbursement structure
                            8.7.1.3. Competitive scenario
                            8.7.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
                        8.7.2. Saudi Arabia
                            8.7.2.1. Key country dynamics
                            8.7.2.2. Regulatory framework/ reimbursement structure
                            8.7.2.3. Competitive scenario
                            8.7.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
                        8.7.3. Jordan
                            8.7.3.1. Key country dynamics
                            8.7.3.2. Regulatory framework/ reimbursement structure
                            8.7.3.3. Competitive scenario
                            8.7.3.4. Jordan market estimates and forecasts, 2018 to 2030 (USD Million)
                        8.7.4. UAE
                            8.7.4.1. Key country dynamics
                            8.7.4.2. Regulatory framework/ reimbursement structure
                            8.7.4.3. Competitive scenario
                            8.7.4.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
                        8.7.5. Qatar
                            8.7.5.1. Key country dynamics
                            8.7.5.2. Regulatory framework/ reimbursement structure
                            8.7.5.3. Competitive scenario
                            8.7.5.4. Qatar market estimates and forecasts, 2018 to 2030 (USD Million)
                        8.7.6. Egypt
                            8.7.6.1. Key country dynamics
                            8.7.6.2. Regulatory framework/ reimbursement structure
                            8.7.6.3. Competitive scenario
                            8.7.6.4. Egypt market estimates and forecasts, 2018 to 2030 (USD Million)
                        8.7.7. Kuwait
                            8.7.7.1. Key country dynamics
                            8.7.7.2. Regulatory framework/ reimbursement structure
                            8.7.7.3. Competitive scenario
                            8.7.7.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 9. Competitive Landscape
                    9.1. Market Participant Categorization
                    9.2. Recent Developments & Impact Analysis by Key Market Participants
                    9.3. Company Market Share Analysis, 2024
                    9.4. Key Company Profiles
                        9.4.1. BD
                            9.4.1.1. Company overview
                            9.4.1.2. Financial performance
                            9.4.1.3. Product benchmarking
                            9.4.1.4. Strategic initiatives
                        9.4.2. BIOMÉRIEUX
                            9.4.2.1. Company overview
                            9.4.2.2. Financial performance
                            9.4.2.3. Product benchmarking
                            9.4.2.4. Strategic initiatives
                        9.4.3. Bio-Rad Laboratories, Inc.
                            9.4.3.1. Company overview
                            9.4.3.2. Financial performance
                            9.4.3.3. Product benchmarking
                            9.4.3.4. Strategic initiatives
                        9.4.4. Abbott
                            9.4.4.1. Company overview
                            9.4.4.2. Financial performance
                            9.4.4.3. Product benchmarking
                            9.4.4.4. Strategic initiatives
                        9.4.5. Agilent Technologies, Inc.
                            9.4.5.1. Company overview
                            9.4.5.2. Financial performance
                            9.4.5.3. Product benchmarking
                            9.4.5.4. Strategic initiatives
                        9.4.6. Danaher
                            9.4.6.1. Company overview
                            9.4.6.2. Financial performance
                            9.4.6.3. Product benchmarking
                            9.4.6.4. Strategic initiatives
                        9.4.7. Hologic Inc. (Gen Probe)
                            9.4.7.1. Company overview
                            9.4.7.2. Financial performance
                            9.4.7.3. Product benchmarking
                            9.4.7.4. Strategic initiatives
                        9.4.8. Illumina, Inc.
                            9.4.8.1. Company overview
                            9.4.8.2. Financial performance
                            9.4.8.3. Product benchmarking
                            9.4.8.4. Strategic initiatives
                        9.4.9. Grifols
                            9.4.9.1. Company overview
                            9.4.9.2. Financial performance
                            9.4.9.3. Product benchmarking
                            9.4.9.4. Strategic initiatives
                        9.4.10. QIAGEN
                            9.4.10.1. Company overview
                            9.4.10.2. Financial performance
                            9.4.10.3. Product benchmarking
                            9.4.10.4. Strategic initiatives
                        9.4.11. F. Hoffmann-La Roche, Ltd.
                            9.4.11.1. Company overview
                            9.4.11.2. Financial performance
                            9.4.11.3. Product benchmarking
                            9.4.11.4. Strategic initiatives
                        9.4.12. Siemens Healthineers AG
                            9.4.12.1. Company overview
                            9.4.12.2. Financial performance
                            9.4.12.3. Product benchmarking
                            9.4.12.4. Strategic initiatives
                        9.4.13. Sysmex Corporation
                            9.4.13.1. Company overview
                            9.4.13.2. Financial performance
                            9.4.13.3. Product benchmarking
                            9.4.13.4. Strategic initiatives


List of Tables

Table 1 List of secondary sources
Table 2 List of abbreviation
Table 3 North America molecular diagnostics market, by country, 2018 - 2030 (USD Million)
Table 4 North America molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 5 North America molecular diagnostics market, by test location, 2018 - 2030 (USD Million)
Table 6 North America molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 7 North America molecular diagnostics market, by application, 2018 - 2030 (USD Million)
Table 8 U.S. molecular diagnostics, by product, 2018 - 2030 (USD Million)
Table 9 U.S. molecular diagnostics, by test location, 2018 - 2030 (USD Million)
Table 10 U.S. molecular diagnostics, by technology, 2018 - 2030 (USD Million)
Table 11 U.S. molecular diagnostics, by application, 2018 - 2030 (USD Million)
Table 12 Canada molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 13 Canada molecular diagnostics market, by test location, 2018 - 2030 (USD Million)
Table 14 Canada molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 15 Canada molecular diagnostics market, by application, 2018 - 2030 (USD Million)
Table 16 Mexico molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 17 Mexico molecular diagnostics market, by test location, 2018 - 2030 (USD Million)
Table 18 Mexico molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 19 Mexico molecular diagnostics market, by application, 2018 - 2030 (USD Million)
Table 20 Europe molecular diagnostics market, by country, 2018 - 2030 (USD Million)
Table 21 Europe molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 22 Europe molecular diagnostics market, by test location, 2018 - 2030 (USD Million)
Table 23 Europe molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 24 Europe molecular diagnostics market, by application, 2018 - 2030 (USD Million)
Table 25 UK molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 26 UK molecular diagnostics market, by test location, 2018 - 2030 (USD Million)
Table 27 UK molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 28 UK molecular diagnostics market, by application, 2018 - 2030 (USD Million)
Table 29 Germany molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 30 Germany molecular diagnostics market, by test location, 2018 - 2030 (USD Million)
Table 31 Germany molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 32 Germany molecular diagnostics market, by application, 2018 - 2030 (USD Million)
Table 33 France molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 34 France molecular diagnostics market, by test location, 2018 - 2030 (USD Million)
Table 35 France molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 36 France molecular diagnostics market, by application, 2018 - 2030 (USD Million)
Table 37 Spain molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 38 Spain molecular diagnostics market, by test location, 2018 - 2030 (USD Million)
Table 39 Spain molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 40 Spain molecular diagnostics market, by application, 2018 - 2030 (USD Million)
Table 41 Italy molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 42 Italy molecular diagnostics market, by test location, 2018 - 2030 (USD Million)
Table 43 Italy molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 44 Italy molecular diagnostics market, by application, 2018 - 2030 (USD Million)
Table 45 Belgium molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 46 Belgium molecular diagnostics market, by test location, 2018 - 2030 (USD Million)
Table 47 Belgium molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 48 Belgium molecular diagnostics market, by application, 2018 - 2030 (USD Million)
Table 49 Switzerland molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 50 Switzerland molecular diagnostics market, by test location, 2018 - 2030 (USD Million)
Table 51 Switzerland molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 52 Switzerland molecular diagnostics market, by application, 2018 - 2030 (USD Million)
Table 53 Netherlands molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 54 Netherlands molecular diagnostics market, by test location, 2018 - 2030 (USD Million)
Table 55 Netherlands molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 56 Netherlands molecular diagnostics market, by application, 2018 - 2030 (USD Million)
Table 57 Poland molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 58 Poland molecular diagnostics market, by test location, 2018 - 2030 (USD Million)
Table 59 Poland molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 60 Poland molecular diagnostics market, by application, 2018 - 2030 (USD Million)
Table 61 Austria molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 62 Austria molecular diagnostics market, by test location, 2018 - 2030 (USD Million)
Table 63 Austria molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 64 Austria molecular diagnostics market, by application, 2018 - 2030 (USD Million)
Table 65 Denmark molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 66 Denmark molecular diagnostics market, by test location, 2018 - 2030 (USD Million)
Table 67 Denmark molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 68 Denmark molecular diagnostics market, by application, 2018 - 2030 (USD Million)
Table 69 Sweden molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 70 Sweden molecular diagnostics market, by test location, 2018 - 2030 (USD Million)
Table 71 Sweden molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 72 Sweden molecular diagnostics market, by application, 2018 - 2030 (USD Million)
Table 73 Turkey molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 74 Turkey molecular diagnostics market, by test location, 2018 - 2030 (USD Million)
Table 75 Turkey molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 76 Turkey molecular diagnostics market, by application, 2018 - 2030 (USD Million)
Table 77 Norway molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 78 Norway molecular diagnostics market, by test location, 2018 - 2030 (USD Million)
Table 79 Norway molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 80 Norway molecular diagnostics market, by application, 2018 - 2030 (USD Million)
Table 81 Asia Pacific molecular diagnostics market, by country, 2018 - 2030 (USD Million)
Table 82 Asia Pacific molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 83 Asia Pacific molecular diagnostics market, by test location, 2018 - 2030 (USD Million)
Table 84 Asia Pacific molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 85 Asia Pacific molecular diagnostics market, by application, 2018 - 2030 (USD Million)
Table 86 Japan molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 87 Japan molecular diagnostics market, by test location, 2018 - 2030 (USD Million)
Table 88 Japan molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 89 Japan molecular diagnostics market, by application, 2018 - 2030 (USD Million)
Table 90 China molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 91 China molecular diagnostics market, by test location, 2018 - 2030 (USD Million)
Table 92 China molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 93 China molecular diagnostics market, by application, 2018 - 2030 (USD Million)
Table 94 India molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 95 India molecular diagnostics market, by test location, 2018 - 2030 (USD Million)
Table 96 India molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 97 India molecular diagnostics market, by application, 2018 - 2030 (USD Million)
Table 98 Australia molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 99 Australia molecular diagnostics market, by test location, 2018 - 2030 (USD Million)
Table 100 Australia molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 101 Australia molecular diagnostics market, by application, 2018 - 2030 (USD Million)
Table 102 New Zealand molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 103 New Zealand molecular diagnostics market, by test location, 2018 - 2030 (USD Million)
Table 104 New Zealand molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 105 New Zealand molecular diagnostics market, by application, 2018 - 2030 (USD Million)
Table 106 Sri Lanka molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 107 Sri Lanka molecular diagnostics market, by test location, 2018 - 2030 (USD Million)
Table 108 Sri Lanka molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 109 Sri Lanka molecular diagnostics market, by application, 2018 - 2030 (USD Million)
Table 110 Malaysia molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 111 Malaysia molecular diagnostics market, by test location, 2018 - 2030 (USD Million)
Table 112 Malaysia molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 113 Malaysia molecular diagnostics market, by application, 2018 - 2030 (USD Million)
Table 114 Thailand molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 115 Thailand molecular diagnostics market, by test location, 2018 - 2030 (USD Million)
Table 116 Thailand molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 117 Thailand molecular diagnostics market, by application, 2018 - 2030 (USD Million)
Table 118 Vietnam molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 119 Vietnam molecular diagnostics market, by test location, 2018 - 2030 (USD Million)
Table 120 Vietnam molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 121 Vietnam molecular diagnostics market, by application, 2018 - 2030 (USD Million)
Table 122 Singapore molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 123 Singapore molecular diagnostics market, by test location, 2018 - 2030 (USD Million)
Table 124 Singapore molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 125 Singapore molecular diagnostics market, by application, 2018 - 2030 (USD Million)
Table 126 Latin America molecular diagnostics market, by country, 2018 - 2030 (USD Million)
Table 127 Latin America molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 128 Latin America molecular diagnostics market, by test location, 2018 - 2030 (USD Million)
Table 129 Latin America molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 130 Latin America molecular diagnostics market, by application, 2018 - 2030 (USD Million)
Table 131 Brazil molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 132 Brazil molecular diagnostics market, by test location, 2018 - 2030 (USD Million)
Table 133 Brazil molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 134 Brazil molecular diagnostics market, by application, 2018 - 2030 (USD Million)
Table 135 Colombia molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 136 Colombia molecular diagnostics market, by test location, 2018 - 2030 (USD Million)
Table 137 Colombia molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 138 Colombia molecular diagnostics market, by application, 2018 - 2030 (USD Million)
Table 139 Chile molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 140 Chile molecular diagnostics market, by test location, 2018 - 2030 (USD Million)
Table 141 Chile molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 142 Chile molecular diagnostics market, by application, 2018 - 2030 (USD Million)
Table 143 Peru molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 144 Peru molecular diagnostics market, by test location, 2018 - 2030 (USD Million)
Table 145 Peru molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 146 Peru molecular diagnostics market, by application, 2018 - 2030 (USD Million)
Table 147 Argentina molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 148 Argentina molecular diagnostics market, by test location, 2018 - 2030 (USD Million)
Table 149 Argentina molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 150 Argentina molecular diagnostics market, by application, 2018 - 2030 (USD Million)
Table 151 MEA molecular diagnostics market, by country 2018 - 2030 (USD Million)
Table 152 MEA molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 153 MEA molecular diagnostics market, by test location, 2018 - 2030 (USD Million)
Table 154 MEA molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 155 MEA molecular diagnostics market, by application, 2018 - 2030 (USD Million)
Table 156 South Africa molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 157 South Africa molecular diagnostics market, by test location, 2018 - 2030 (USD Million)
Table 158 South Africa molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 159 South Africa molecular diagnostics market, by application, 2018 - 2030 (USD Million)
Table 160 Saudi Arabia molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 161 Saudi Arabia molecular diagnostics market, by test location, 2018 - 2030 (USD Million)
Table 162 Saudi Arabia molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 163 Saudi Arabia molecular diagnostics market, by application, 2018 - 2030 (USD Million)
Table 164 Jordan molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 165 Jordan molecular diagnostics market, by test location, 2018 - 2030 (USD Million)
Table 166 Jordan molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 167 Jordan molecular diagnostics market, by application, 2018 - 2030 (USD Million)
Table 168 UAE molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 169 UAE molecular diagnostics market, by test location, 2018 - 2030 (USD Million)
Table 170 UAE molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 171 UAE molecular diagnostics market, by application, 2018 - 2030 (USD Million)
Table 172 Qatar molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 173 Qatar molecular diagnostics market, by test location, 2018 - 2030 (USD Million)
Table 174 Qatar molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 175 Qatar molecular diagnostics market, by application, 2018 - 2030 (USD Million)
Table 176 Kuwait molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 177 Kuwait molecular diagnostics market, by test location, 2018 - 2030 (USD Million)
Table 178 Kuwait molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 179 Kuwait molecular diagnostics market, by application, 2018 - 2030 (USD Million)
Table 180 Egypt molecular diagnostics market, by product, 2018 - 2030 (USD Million)
Table 181 Egypt molecular diagnostics market, by test location, 2018 - 2030 (USD Million)
Table 182 Egypt molecular diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 183 Egypt molecular diagnostics market, by application, 2018 - 2030 (USD Million)


List of Figures

Fig. 1 Molecular diagnostics market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Market snapshot
Fig. 10 Product and test location segment snapshot
Fig. 11 Technology segment snapshot
Fig. 12 Application segment snapshot
Fig. 13 Competitive landscape snapshot
Fig. 14 Molecular diagnostics market value, 2024 (USD Billion)
Fig. 15 Market dynamics
Fig. 16 Global number of people aged over 60 years or over (thousands) in 2024
Fig. 17 Global estimated cancer incidence in different elderly age groups, 2022 (Million)
Fig. 18 General trend shifts from laboratory to point-of-care
Fig. 19 Incidence of cancer in North America, 2022-2050
Fig. 20 Incidence of cancer in Europe, 2022-2050
Fig. 21 Incidence of cancer in Asia Pacific, 2022-2050
Fig. 22 Incidence of cancer in Latin America, 2022-2050
Fig. 23 Incidence of cancer in Africa, 2022-2050
Fig. 24 Incidence of cancer in Oceania, 2022-2050
Fig. 25 Sources of healthcare financing according to country income, 2020 (%)
Fig. 26 Porter’s five forces analysis
Fig. 27 PESTLE analysis
Fig. 28 Molecular diagnostics market: Product outlook and key takeaways
Fig. 29 Molecular diagnostics market: Product movement analysis
Fig. 30 Instruments market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 Reagents market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Molecular diagnostics market: Technology outlook and key takeaways
Fig. 34 Molecular diagnostics market: Technology movement analysis
Fig. 35 PCR market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 Multiplex PCR market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Other PCR market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 Nucleic acid extraction market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 Instruments market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 Reagents market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 43 In situ hybridization market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 Instruments market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 45 Reagents market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 46 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 47 INAAT market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 Instruments market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 49 Reagents market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 50 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 51 Chips and microarrays market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 52 Instruments market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 53 Reagents market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 54 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 55 Mass spectrometry market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 56 Instruments market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 57 Reagents market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 58 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 59 Sequencing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 60 Instruments market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 61 Reagents market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 62 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 63 Transcription mediated amplification (TMA) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 64 Instruments market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 65 Reagents market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 66 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 67 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 68 Instruments market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 69 Reagents market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 70 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 71 Molecular diagnostics market: Application outlook and key takeaways
Fig. 72 Molecular diagnostics market: Application movement analysis
Fig. 73 Oncology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 74 Breast cancer market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 75 Prostate cancer market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 76 Colorectal cancer market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 77 Cervical cancer market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 78 Kidney cancer market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 79 Liver cancer market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 80 Lung cancer market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 81 Blood cancer market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 82 Other cancer market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 83 Pharmacogenomics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 84 Infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 85 Methicillin-resistant staphylococcus aureus (MRSA) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 86 Clostridium difficile market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 87 Vancomycin-resistant enterococci (VRE) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 88 Carbapenem-resistant bacteria market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 89 Flu market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 90 Respiratory syncytial virus (RSV) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 91 Candida market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 92 Tuberculosis and drug-resistant TB market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 93 Meningitis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 94 Gastrointestinal panel testing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 95 Chlamydia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 96 Gonorrhea market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 97 HIV market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 98 Hepatitis C market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 99 Hepatitis B market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 100 Other infectious diseases market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 101 Genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 102 Newborn screening market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 103 Predictive and presymptomatic testing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 104 Other genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 105 Neurological disease market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 106 Cardiovascular disease market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 107 Microbiology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 108 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 109 Molecular diagnostics market: Test location outlook and key takeaways
Fig. 110 Molecular diagnostics market: Test location movement analysis
Fig. 111 Point of care market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 112 Self-test or over-the-counter market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 113 Central laboratories market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 114 Molecular diagnostics market revenue, by region, 2024 & 2030 (USD Million)
Fig. 115 Regional marketplace: Key takeaways
Fig. 116 Regional marketplace: Key takeaways
Fig. 117 North America molecular diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 118 Key country dynamics
Fig. 119 Estimated cancer incidence in U.S., 2024 - 2030
Fig. 120 U.S. molecular diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 121 Key country dynamics
Fig. 122 Estimated cancer incidence in Canada, 2024 - 2030
Fig. 123 Canada molecular diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 124 Key country dynamics
Fig. 125 Estimated cancer incidence in Mexico, 2024 - 2030
Fig. 126 Mexico molecular diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 127 Europe molecular diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 128 Key country dynamics
Fig. 129 Estimated cancer incidence in UK, 2024 - 2030
Fig. 130 UK molecular diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 131 Key country dynamics
Fig. 132 Estimated cancer incidence in Germany, 2024 - 2030
Fig. 133 Germany molecular diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 134 Key country dynamics
Fig. 135 Estimated cancer incidence in France, 2024 - 2030
Fig. 136 France molecular diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 137 Key country dynamics
Fig. 138 Estimated cancer incidence in Spain, 2024 - 2030
Fig. 139 Spain molecular diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 140 Key country dynamics
Fig. 141 Estimated cancer incidence in Italy, 2024 - 2030
Fig. 142 Italy molecular diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 143 Key country dynamics
Fig. 144 Estimated cancer incidence in Denmark, 2024 - 2030
Fig. 145 Denmark molecular diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 146 Key country dynamics
Fig. 147 Sweden molecular diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 148 Key country dynamics
Fig. 149 Norway molecular diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 150 Key country dynamics
Fig. 151 Belgium molecular diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 152 Key country dynamics
Fig. 153 Switzerland molecular diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 154 Key country dynamics
Fig. 155 Netherlands molecular diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 156 Key country dynamics
Fig. 157 Poland molecular diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 158 Key country dynamics
Fig. 159 Austria molecular diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 160 Key country dynamics
Fig. 161 Turkey molecular diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 162 Rest of Europe molecular diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 163 Asia Pacific molecular diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 164 Key country dynamics
Fig. 165 Japan molecular diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 166 Key country dynamics
Fig. 167 China molecular diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 168 Key country dynamics
Fig. 169 India molecular diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 170 Key country dynamics
Fig. 171 Australia molecular diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 172 Key country dynamics
Fig. 173 Thailand molecular diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 174 Key country dynamics
Fig. 175 New Zealand molecular diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 176 Key country dynamics
Fig. 177 Sri Lanka molecular diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 178 Key country dynamics
Fig. 179 Malaysia molecular diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 180 Key country dynamics
Fig. 181 Vietnam molecular diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 182 Key country dynamics
Fig. 183 Singapore molecular diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 184 Rest of Asia Pacific molecular diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 185 Latin America molecular diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 186 Key country dynamics
Fig. 187 Brazil molecular diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 188 Key country dynamics
Fig. 189 Argentina molecular diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 190 Key country dynamics
Fig. 191 Colombia molecular diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 192 Key country dynamics
Fig. 193 Chile molecular diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 194 Key country dynamics
Fig. 195 Peru molecular diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 196 Rest of Latin America molecular diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 197 MEA molecular diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 198 Key country dynamics
Fig. 199 Estimated cancer incidence in South Africa, 2024 - 2030
Fig. 200 South Africa molecular diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 201 Key country dynamics
Fig. 202 Estimated cancer incidence in Saudi Arabia, 2024 - 2030
Fig. 203 Saudi Arabia molecular diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 204 Key country dynamics
Fig. 205 Estimated new cancer cases in UAE, 2024 - 2030
Fig. 206 UAE molecular diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 207 Key country dynamics
Fig. 208 Kuwait molecular diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 209 Key country dynamics
Fig. 210 Jordan molecular diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 211 Key country dynamics
Fig. 212 Qatar molecular diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 213 Key country dynamics
Fig. 214 Egypt molecular diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 215 Rest of MEA molecular diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 216 Key company categorization
Fig. 217 Global company market share analysis for molecular diagnostics, 2024
Fig. 218 North America company market share analysis for molecular diagnostics, 2024
Fig. 219 Europe company market share analysis for molecular diagnostics, 2024
Fig. 220 Asia Pacific company market share analysis for molecular diagnostics, 2024
Fig. 221 Latin America company market share analysis for molecular diagnostics, 2024
Fig. 222 MEA company market share analysis for molecular diagnostics, 2024
Fig. 223 Strategy mapping

What questions do you have? Get quick response from our industry experts. Request a Free Consultation

Market Segmentation

  • Molecular Diagnostics Product Outlook (Revenue, USD Million, 2018 - 2030)
    • Instruments
    • Regards
    • Others
  • Molecular Diagnostics Test Location Outlook (Revenue, USD Million, 2018 - 2030)
    • Point of care
    • Self-test or OTC
    • Central laboratories
  • Molecular Diagnostics Technology Outlook (Revenue, USD Million, 2018 - 2030)
    • Polymerase chain reaction (PCR)
      • PCR, by Procedure
        • Nucleic Acid Extraction
        • Others
      • PCR, by Type
        • Multiplex PCR
        • Other PCR
      • PCR, by Product
        • Instruments
        • Reagents
        • Others
    • In Situ Hybridization (ISH)
      • Instruments
      • Reagents
      • Others
    • Isothermal Nucleic Acid Amplification Technology (INAAT)
      • Instruments
      • Reagents
      • Others
    • Chips and Microarrays
      • Instruments
      • Reagents
      • Others
    • Mass Spectrometry
      • Instruments
      • Reagents
      • Others
    • Transcription Mediated Amplification (TMA)
      • Instruments
      • Reagents
      • Others
    • Others
      • Instruments
      • Reagents
      • Others
  • Molecular Diagnostics Application Outlook (Revenue, USD Million, 2018 - 2030)
    • Oncology
      • Breast Cancer
      • Prostate Cancer
      • Colorectal Cancer
      • Cervical
      • Kidney
      • Liver
      • Blood
      • Lung
      • Other
    • Pharmacogenomics
    • Infectious disease
      • MRSA
      • Clostridium difficile
      • Vancomycin-resistant enterococci
      • Carbapenem-resistant bacteria testing
      • Flu
      • Respiratory syncytial virus (RSV)
      • Candida
      • Tuberculosis and drug-resistant TB
      • Meningitis
      • Gastro-intestinal panel testing
      • Chlamydia
      • Gonorrhea
      • HIV
      • Hepatitis C
      • Hepatitis B
      • Other Infectious Diseases
    • Genetic testing
      • Newborn screening
      • Predictive and presymptomatic testing
      • Others
    • Neurological disease
    • Cardiovascular disease
    • Microbiology
    • Others
  • Molecular Diagnostics Regional Outlook (Revenue USD Million, 2018 - 2030)
    • North America
      • North America Molecular Diagnostics Market, By Product
        • Instruments
        • Regards
        • Others
      • North America Molecular Diagnostics Market, By Test Location
        • Point of care
        • Self test or OTC
        • Central laboratories
      • North America Molecular Diagnostics Market, By Technology
        • Polymerase chain reaction (PCR)
          • PCR, by Procedure
            • Nucleic Acid Extraction
            • Others
          • PCR, by Type
            • Multiplex PCR
            • Other PCR
          • PCR, by Product
            • Instruments
            • Reagents
            • Others
        • In Situ Hybridization (ISH)
          • Instruments
          • Reagents
          • Others
        • Isothermal Nucleic Acid Amplification Technology (INAAT)
          • Instruments
          • Reagents
          • Others
        • Chips and Microarrays
          • Instruments
          • Reagents
          • Others
        • Mass Spectrometry
          • Instruments
          • Reagents
          • Others
        • Transcription Mediated Amplification (TMA)
          • Instruments
          • Reagents
          • Others
        • Others
          • Instruments
          • Reagents
          • Others
      • North America Molecular Diagnostics Market, By Application
        • Oncology
          • Breast Cancer
          • Prostate Cancer
          • Colorectal Cancer
          • Cervical
          • Kidney
          • Liver
          • Blood
          • Lung
          • Other
        • Pharmacogenomics
        • Infectious disease
          • MRSA
          • Clostridium difficile
          • Vancomycin-resistant enterococci
          • Carbapenem-resistant bacteria testing
          • Flu
          • Respiratory syncytial virus (RSV)
          • Candida
          • Tuberculosis and drug-resistant TB
          • Meningitis
          • Gastro-intestinal panel testing
          • Chlamydia
          • Gonorrhea
          • HIV
          • Hepatitis C
          • Hepatitis B
          • Other Infectious Diseases
        • Genetic testing
          • Newborn screening
          • Predictive and presymptomatic testing
          • Others
        • Neurological disease
        • Cardiovascular disease
        • Microbiology
        • Others
      • U.S.
        • U.S. Molecular Diagnostics Market, By Product
          • Instruments
          • Reagents
          • Others
        • U.S. Molecular Diagnostics Market, By Test Location
          • Point of care
          • Self test or OTC
          • Central laboratories
        • U.S. Molecular Diagnostics Market, By Technology
          • Polymerase chain reaction (PCR)
            • PCR, by Procedure
              • Nucleic Acid Extraction
              • Others
            • PCR, by Type
              • Multiplex PCR
              • Other PCR
            • PCR, by Product
              • Instruments
              • Reagents
              • Others
          • In Situ Hybridization (ISH)
            • Instruments
            • Reagents
            • Others
          • Isothermal Nucleic Acid Amplification Technology (INAAT)
            • Instruments
            • Reagents
            • Others
          • Chips and Microarrays
            • Instruments
            • Reagents
            • Others
          • Mass Spectrometry
            • Instruments
            • Reagents
            • Others
          • Transcription Mediated Amplification (TMA)
            • Instruments
            • Reagents
            • Others
          • Others
            • Instruments
            • Reagents
            • Others
        • U.S. Molecular Diagnostics Market, By Application
          • Oncology
            • Breast Cancer
            • Prostate Cancer
            • Colorectal Cancer
            • Cervical
            • Kidney
            • Liver
            • Blood
            • Lung
            • Other
          • Pharmacogenomics
          • Infectious disease
            • MRSA
            • Clostridium difficile
            • Vancomycin-resistant enterococci
            • Carbapenem-resistant bacteria testing
            • Flu
            • Respiratory syncytial virus (RSV)
            • Candida
            • Tuberculosis and drug-resistant TB
            • Meningitis
            • Gastro-intestinal panel testing
            • Chlamydia
            • Gonorrhea
            • HIV
            • Hepatitis C
            • Hepatitis B
            • Other Infectious Diseases
          • Genetic testing
            • Newborn screening
            • Predictive and presymptomatic testing
            • Others
          • Neurological disease
          • Cardiovascular disease
          • Microbiology
          • Others
      • Canada
        • Canada Molecular Diagnostics Market, By Product
          • Instruments
          • Reagents
          • Others
        • Canada Molecular Diagnostics Market, By Test Location
          • Point of care
          • Self test or OTC
          • Central laboratories
        • Canada Molecular Diagnostics Market, By Technology
          • Polymerase chain reaction (PCR)
            • PCR, by Procedure
              • Nucleic Acid Extraction
              • Others
            • PCR, by Type
              • Multiplex PCR
              • Other PCR
            • PCR, by Product
              • Instruments
              • Reagents
              • Others
          • In Situ Hybridization (ISH)
            • Instruments
            • Reagents
            • Others
          • Isothermal Nucleic Acid Amplification Technology (INAAT)
            • Instruments
            • Reagents
            • Others
          • Chips and Microarrays
            • Instruments
            • Reagents
            • Others
          • Mass Spectrometry
            • Instruments
            • Reagents
            • Others
          • Transcription Mediated Amplification (TMA)
            • Instruments
            • Reagents
            • Others
          • Others
            • Instruments
            • Reagents
            • Others
        • Canada Molecular Diagnostics Market, By Application
          • Oncology
            • Breast Cancer
            • Prostate Cancer
            • Colorectal Cancer
            • Cervical
            • Kidney
            • Liver
            • Blood
            • Lung
            • Other
          • Pharmacogenomics
          • Infectious disease
            • MRSA
            • Clostridium difficile
            • Vancomycin-resistant enterococci
            • Carbapenem-resistant bacteria testing
            • Flu
            • Respiratory syncytial virus (RSV)
            • Candida
            • Tuberculosis and drug-resistant TB
            • Meningitis
            • Gastro-intestinal panel testing
            • Chlamydia
            • Gonorrhea
            • HIV
            • Hepatitis C
            • Hepatitis B
            • Other Infectious Diseases
          • Genetic testing
            • Newborn screening
            • Predictive and presymptomatic testing
            • Others
          • Neurological disease
          • Cardiovascular disease
          • Microbiology
          • Others
      • Mexico
        • Mexico Molecular Diagnostics Market, By Product
          • Instruments
          • Reagents
          • Others
        • Mexico Molecular Diagnostics Market, By Test Location
          • Point of care
          • Self test or OTC
          • Central laboratories
        • Mexico Molecular Diagnostics Market, By Technology
          • Polymerase chain reaction (PCR)
            • PCR, by Procedure
              • Nucleic Acid Extraction
              • Others
            • PCR, by Type
              • Multiplex PCR
              • Other PCR
            • PCR, by Product
              • Instruments
              • Reagents
              • Others
          • In Situ Hybridization (ISH)
            • Instruments
            • Reagents
            • Others
          • Isothermal Nucleic Acid Amplification Technology (INAAT)
            • Instruments
            • Reagents
            • Others
          • Chips and Microarrays
            • Instruments
            • Reagents
            • Others
          • Mass Spectrometry
            • Instruments
            • Reagents
            • Others
          • Transcription Mediated Amplification (TMA)
            • Instruments
            • Reagents
            • Others
          • Others
            • Instruments
            • Reagents
            • Others
        • Mexico Molecular Diagnostics Market, By Application
          • Oncology
            • Breast Cancer
            • Prostate Cancer
            • Colorectal Cancer
            • Cervical
            • Kidney
            • Liver
            • Blood
            • Lung
            • Other
          • Pharmacogenomics
          • Infectious disease
            • MRSA
            • Clostridium difficile
            • Vancomycin-resistant enterococci
            • Carbapenem-resistant bacteria testing
            • Flu
            • Respiratory syncytial virus (RSV)
            • Candida
            • Tuberculosis and drug-resistant TB
            • Meningitis
            • Gastro-intestinal panel testing
            • Chlamydia
            • Gonorrhea
            • HIV
            • Hepatitis C
            • Hepatitis B
            • Other Infectious Diseases
          • Genetic testing
            • Newborn screening
            • Predictive and presymptomatic testing
            • Others
          • Neurological disease
          • Cardiovascular disease
          • Microbiology
          • Others
    • Europe
      • Europe Molecular Diagnostics Market, By Product
        • Instruments
        • Reagents
        • Others
      • Europe Molecular Diagnostics Market, By Test Location
        • Point of care
        • Self test or OTC
        • Central laboratories
      • Europe Molecular Diagnostics Market, By Technology
        • Polymerase chain reaction (PCR)
          • PCR, by Procedure
            • Nucleic Acid Extraction
            • Others
          • PCR, by Type
            • Multiplex PCR
            • Other PCR
          • PCR, by Product
            • Instruments
            • Reagents
            • Others
        • In Situ Hybridization (ISH)
          • Instruments
          • Reagents
          • Others
        • Isothermal Nucleic Acid Amplification Technology (INAAT)
          • Instruments
          • Reagents
          • Others
        • Chips and Microarrays
          • Instruments
          • Reagents
          • Others
        • Mass Spectrometry
          • Instruments
          • Reagents
          • Others
        • Transcription Mediated Amplification (TMA)
          • Instruments
          • Reagents
          • Others
        • Others
          • Instruments
          • Reagents
          • Others
      • Europe Molecular Diagnostics Market, By Application
        • Oncology
          • Breast Cancer
          • Prostate Cancer
          • Colorectal Cancer
          • Cervical
          • Kidney
          • Liver
          • Blood
          • Lung
          • Other
        • Pharmacogenomics
        • Infectious disease
          • MRSA
          • Clostridium difficile
          • Vancomycin-resistant enterococci
          • Carbapenem-resistant bacteria testing
          • Flu
          • Respiratory syncytial virus (RSV)
          • Candida
          • Tuberculosis and drug-resistant TB
          • Meningitis
          • Gastro-intestinal panel testing
          • Chlamydia
          • Gonorrhea
          • HIV
          • Hepatitis C
          • Hepatitis B
          • Other Infectious Diseases
        • Genetic testing
          • Newborn screening
          • Predictive and presymptomatic testing
          • Others
        • Neurological disease
        • Cardiovascular disease
        • Microbiology
        • Others
      • Germany
        • Germany Molecular Diagnostics Market, By Product
          • Instruments
          • Reagents
          • Others
        • Germany Molecular Diagnostics Market, By Test Location
          • Point of care
          • Self test or OTC
          • Central laboratories
        • Germany Molecular Diagnostics Market, By Technology
          • Polymerase chain reaction (PCR)
            • PCR, by Procedure
              • Nucleic Acid Extraction
              • Others
            • PCR, by Type
              • Multiplex PCR
              • Other PCR
            • PCR, by Product
              • Instruments
              • Reagents
              • Others
          • In Situ Hybridization (ISH)
            • Instruments
            • Reagents
            • Others
          • Isothermal Nucleic Acid Amplification Technology (INAAT)
            • Instruments
            • Reagents
            • Others
          • Chips and Microarrays
            • Instruments
            • Reagents
            • Others
          • Mass Spectrometry
            • Instruments
            • Reagents
            • Others
          • Transcription Mediated Amplification (TMA)
            • Instruments
            • Reagents
            • Others
          • Others
            • Instruments
            • Reagents
            • Others
        • Germany Molecular Diagnostics Market, By Application
          • Oncology
            • Breast Cancer
            • Prostate Cancer
            • Colorectal Cancer
            • Cervical
            • Kidney
            • Liver
            • Blood
            • Lung
            • Other
          • Pharmacogenomics
          • Infectious disease
            • MRSA
            • Clostridium difficile
            • Vancomycin-resistant enterococci
            • Carbapenem-resistant bacteria testing
            • Flu
            • Respiratory syncytial virus (RSV)
            • Candida
            • Tuberculosis and drug-resistant TB
            • Meningitis
            • Gastro-intestinal panel testing
            • Chlamydia
            • Gonorrhea
            • HIV
            • Hepatitis C
            • Hepatitis B
            • Other Infectious Diseases
          • Genetic testing
            • Newborn screening
            • Predictive and presymptomatic testing
            • Others
          • Neurological disease
          • Cardiovascular disease
          • Microbiology
          • Others
      • UK
        • UK Molecular Diagnostics Market, By Product
          • Instruments
          • Reagents
          • Others
        • UK Molecular Diagnostics Market, By Test Location
          • Point of care
          • Self test or OTC
          • Central laboratories
        • UK Molecular Diagnostics Market, By Technology
          • Polymerase chain reaction (PCR)
            • PCR, by Procedure
              • Nucleic Acid Extraction
              • Others
            • PCR, by Type
              • Multiplex PCR
              • Other PCR
            • PCR, by Product
              • Instruments
              • Reagents
              • Others
          • In Situ Hybridization (ISH)
            • Instruments
            • Reagents
            • Others
          • Isothermal Nucleic Acid Amplification Technology (INAAT)
            • Instruments
            • Reagents
            • Others
          • Chips and Microarrays
            • Instruments
            • Reagents
            • Others
          • Mass Spectrometry
            • Instruments
            • Reagents
            • Others
          • Transcription Mediated Amplification (TMA)
            • Instruments
            • Reagents
            • Others
          • Others
            • Instruments
            • Reagents
            • Others
        • UK Molecular Diagnostics Market, By Application
          • Oncology
            • Breast Cancer
            • Prostate Cancer
            • Colorectal Cancer
            • Cervical
            • Kidney
            • Liver
            • Blood
            • Lung
            • Other
          • Pharmacogenomics
          • Infectious disease
            • MRSA
            • Clostridium difficile
            • Vancomycin-resistant enterococci
            • Carbapenem-resistant bacteria testing
            • Flu
            • Respiratory syncytial virus (RSV)
            • Candida
            • Tuberculosis and drug-resistant TB
            • Meningitis
            • Gastro-intestinal panel testing
            • Chlamydia
            • Gonorrhea
            • HIV
            • Hepatitis C
            • Hepatitis B
            • Other Infectious Diseases
          • Genetic testing
            • Newborn screening
            • Predictive and presymptomatic testing
            • Others
          • Neurological disease
          • Cardiovascular disease
          • Microbiology
          • Others
      • France
        • France Molecular Diagnostics Market, By Product
          • Instruments
          • Reagents
          • Others
        • France Molecular Diagnostics Market, By Test Location
          • Point of care
          • Self test or OTC
          • Central laboratories
        • France Molecular Diagnostics Market, By Technology
          • Polymerase chain reaction (PCR)
            • PCR, by Procedure
              • Nucleic Acid Extraction
              • Others
            • PCR, by Type
              • Multiplex PCR
              • Other PCR
            • PCR, by Product
              • Instruments
              • Reagents
              • Others
          • In Situ Hybridization (ISH)
            • Instruments
            • Reagents
            • Others
          • Isothermal Nucleic Acid Amplification Technology (INAAT)
            • Instruments
            • Reagents
            • Others
          • Chips and Microarrays
            • Instruments
            • Reagents
            • Others
          • Mass Spectrometry
            • Instruments
            • Reagents
            • Others
          • Transcription Mediated Amplification (TMA)
            • Instruments
            • Reagents
            • Others
          • Others
            • Instruments
            • Reagents
            • Others
        • France Molecular Diagnostics Market, By Application
          • Oncology
            • Breast Cancer
            • Prostate Cancer
            • Colorectal Cancer
            • Cervical
            • Kidney
            • Liver
            • Blood
            • Lung
            • Other
          • Pharmacogenomics
          • Infectious disease
            • MRSA
            • Clostridium difficile
            • Vancomycin-resistant enterococci
            • Carbapenem-resistant bacteria testing
            • Flu
            • Respiratory syncytial virus (RSV)
            • Candida
            • Tuberculosis and drug-resistant TB
            • Meningitis
            • Gastro-intestinal panel testing
            • Chlamydia
            • Gonorrhea
            • HIV
            • Hepatitis C
            • Hepatitis B
            • Other Infectious Diseases
          • Genetic testing
            • Newborn screening
            • Predictive and presymptomatic testing
            • Others
          • Neurological disease
          • Cardiovascular disease
          • Microbiology
          • Others
      • Italy
        • Italy Molecular Diagnostics Market, By Product
          • Instruments
          • Reagents
          • Others
        • Italy Molecular Diagnostics Market, By Test Location
          • Point of care
          • Self test or OTC
          • Central laboratories
        • Italy Molecular Diagnostics Market, By Technology
          • Polymerase chain reaction (PCR)
            • PCR, by Procedure
              • Nucleic Acid Extraction
              • Others
            • PCR, by Type
              • Multiplex PCR
              • Other PCR
            • PCR, by Product
              • Instruments
              • Reagents
              • Others
          • In Situ Hybridization (ISH)
            • Instruments
            • Reagents
            • Others
          • Isothermal Nucleic Acid Amplification Technology (INAAT)
            • Instruments
            • Reagents
            • Others
          • Chips and Microarrays
            • Instruments
            • Reagents
            • Others
          • Mass Spectrometry
            • Instruments
            • Reagents
            • Others
          • Transcription Mediated Amplification (TMA)
            • Instruments
            • Reagents
            • Others
          • Others
            • Instruments
            • Reagents
            • Others
        • Italy Molecular Diagnostics Market, By Application
          • Oncology
            • Breast Cancer
            • Prostate Cancer
            • Colorectal Cancer
            • Cervical
            • Kidney
            • Liver
            • Blood
            • Lung
            • Other
          • Pharmacogenomics
          • Infectious disease
            • MRSA
            • Clostridium difficile
            • Vancomycin-resistant enterococci
            • Carbapenem-resistant bacteria testing
            • Flu
            • Respiratory syncytial virus (RSV)
            • Candida
            • Tuberculosis and drug-resistant TB
            • Meningitis
            • Gastro-intestinal panel testing
            • Chlamydia
            • Gonorrhea
            • HIV
            • Hepatitis C
            • Hepatitis B
            • Other Infectious Diseases
          • Genetic testing
            • Newborn screening
            • Predictive and presymptomatic testing
            • Others
          • Neurological disease
          • Cardiovascular disease
          • Microbiology
          • Others
      • Spain
        • Spain Molecular Diagnostics Market, By Product
          • Instruments
          • Regards
          • Others
        • Spain Molecular Diagnostics Market, By Test Location
          • Point of care
          • Self test or OTC
          • Central laboratories
        • Spain Molecular Diagnostics Market, By Technology
          • Polymerase chain reaction (PCR)
            • PCR, by Procedure
              • Nucleic Acid Extraction
              • Others
            • PCR, by Type
              • Multiplex PCR
              • Other PCR
            • PCR, by Product
              • Instruments
              • Reagents
              • Others
          • In Situ Hybridization (ISH)
            • Instruments
            • Reagents
            • Others
          • Isothermal Nucleic Acid Amplification Technology (INAAT)
            • Instruments
            • Reagents
            • Others
          • Chips and Microarrays
            • Instruments
            • Reagents
            • Others
          • Mass Spectrometry
            • Instruments
            • Reagents
            • Others
          • Transcription Mediated Amplification (TMA)
            • Instruments
            • Reagents
            • Others
          • Others
            • Instruments
            • Reagents
            • Others
        • Spain Molecular Diagnostics Market, By Application
          • Oncology
            • Breast Cancer
            • Prostate Cancer
            • Colorectal Cancer
            • Cervical
            • Kidney
            • Liver
            • Blood
            • Lung
            • Other
          • Pharmacogenomics
          • Infectious disease
            • MRSA
            • Clostridium difficile
            • Vancomycin-resistant enterococci
            • Carbapenem-resistant bacteria testing
            • Flu
            • Respiratory syncytial virus (RSV)
            • Candida
            • Tuberculosis and drug-resistant TB
            • Meningitis
            • Gastro-intestinal panel testing
            • Chlamydia
            • Gonorrhea
            • HIV
            • Hepatitis C
            • Hepatitis B
            • Other Infectious Diseases
          • Genetic testing
            • Newborn screening
            • Predictive and presymptomatic testing
            • Others
          • Neurological disease
          • Cardiovascular disease
          • Microbiology
          • Others
      • Sweden
        • Sweden Molecular Diagnostics Market, By Product
          • Instruments
          • Regards
          • Others
        • Sweden Molecular Diagnostics Market, By Test Location
          • Point of care
          • Self test or OTC
          • Central laboratories
        • Sweden Molecular Diagnostics Market, By Technology
          • Polymerase chain reaction (PCR)
            • PCR, by Procedure
              • Nucleic Acid Extraction
              • Others
            • PCR, by Type
              • Multiplex PCR
              • Other PCR
            • PCR, by Product
              • Instruments
              • Reagents
              • Others
          • In Situ Hybridization (ISH)
            • Instruments
            • Reagents
            • Others
          • Isothermal Nucleic Acid Amplification Technology (INAAT)
            • Instruments
            • Reagents
            • Others
          • Chips and Microarrays
            • Instruments
            • Reagents
            • Others
          • Mass Spectrometry
            • Instruments
            • Reagents
            • Others
          • Transcription Mediated Amplification (TMA)
            • Instruments
            • Reagents
            • Others
          • Others
            • Instruments
            • Reagents
            • Others
        • Sweden Molecular Diagnostics Market, By Application
          • Oncology
            • Breast Cancer
            • Prostate Cancer
            • Colorectal Cancer
            • Cervical
            • Kidney
            • Liver
            • Blood
            • Lung
            • Other
          • Pharmacogenomics
          • Infectious disease
            • MRSA
            • Clostridium difficile
            • Vancomycin-resistant enterococci
            • Carbapenem-resistant bacteria testing
            • Flu
            • Respiratory syncytial virus (RSV)
            • Candida
            • Tuberculosis and drug-resistant TB
            • Meningitis
            • Gastro-intestinal panel testing
            • Chlamydia
            • Gonorrhea
            • HIV
            • Hepatitis C
            • Hepatitis B
            • Other Infectious Diseases
          • Genetic testing
            • Newborn screening
            • Predictive and presymptomatic testing
            • Others
          • Neurological disease
          • Cardiovascular disease
          • Microbiology
          • Others
      • Denmark
        • Denmark Molecular Diagnostics Market, By Product
          • Instruments
          • Regards
          • Others
        • Denmark Molecular Diagnostics Market, By Test Location
          • Point of care
          • Self test or OTC
          • Central laboratories
        • Denmark Molecular Diagnostics Market, By Technology
          • Polymerase chain reaction (PCR)
            • PCR, by Procedure
              • Nucleic Acid Extraction
              • Others
            • PCR, by Type
              • Multiplex PCR
              • Other PCR
            • PCR, by Product
              • Instruments
              • Reagents
              • Others
          • In Situ Hybridization (ISH)
            • Instruments
            • Reagents
            • Others
          • Isothermal Nucleic Acid Amplification Technology (INAAT)
            • Instruments
            • Reagents
            • Others
          • Chips and Microarrays
            • Instruments
            • Reagents
            • Others
          • Mass Spectrometry
            • Instruments
            • Reagents
            • Others
          • Transcription Mediated Amplification (TMA)
            • Instruments
            • Reagents
            • Others
          • Others
            • Instruments
            • Reagents
            • Others
        • Denmark Molecular Diagnostics Market, By Application
          • Oncology
            • Breast Cancer
            • Prostate Cancer
            • Colorectal Cancer
            • Cervical
            • Kidney
            • Liver
            • Blood
            • Lung
            • Other
          • Pharmacogenomics
          • Infectious disease
            • MRSA
            • Clostridium difficile
            • Vancomycin-resistant enterococci
            • Carbapenem-resistant bacteria testing
            • Flu
            • Respiratory syncytial virus (RSV)
            • Candida
            • Tuberculosis and drug-resistant TB
            • Meningitis
            • Gastro-intestinal panel testing
            • Chlamydia
            • Gonorrhea
            • HIV
            • Hepatitis C
            • Hepatitis B
            • Other Infectious Diseases
          • Genetic testing
            • Newborn screening
            • Predictive and presymptomatic testing
            • Others
          • Neurological disease
          • Cardiovascular disease
          • Microbiology
          • Others
      • Norway
        • Norway Molecular Diagnostics Market, By Product
          • Instruments
          • Regards
          • Others
        • Norway Molecular Diagnostics Market, By Test Location
          • Point of care
          • Self test or OTC
          • Central laboratories
        • Norway Molecular Diagnostics Market, By Technology
          • Polymerase chain reaction (PCR)
            • PCR, by Procedure
              • Nucleic Acid Extraction
              • Others
            • PCR, by Type
              • Multiplex PCR
              • Other PCR
            • PCR, by Product
              • Instruments
              • Reagents
              • Others
          • In Situ Hybridization (ISH)
            • Instruments
            • Reagents
            • Others
          • Isothermal Nucleic Acid Amplification Technology (INAAT)
            • Instruments
            • Reagents
            • Others
          • Chips and Microarrays
            • Instruments
            • Reagents
            • Others
          • Mass Spectrometry
            • Instruments
            • Reagents
            • Others
          • Transcription Mediated Amplification (TMA)
            • Instruments
            • Reagents
            • Others
          • Others
            • Instruments
            • Reagents
            • Others
        • Norway Molecular Diagnostics Market, By Application
          • Oncology
            • Breast Cancer
            • Prostate Cancer
            • Colorectal Cancer
            • Cervical
            • Kidney
            • Liver
            • Blood
            • Lung
            • Other
          • Pharmacogenomics
          • Infectious disease
            • MRSA
            • Clostridium difficile
            • Vancomycin-resistant enterococci
            • Carbapenem-resistant bacteria testing
            • Flu
            • Respiratory syncytial virus (RSV)
            • Candida
            • Tuberculosis and drug-resistant TB
            • Meningitis
            • Gastro-intestinal panel testing
            • Chlamydia
            • Gonorrhea
            • HIV
            • Hepatitis C
            • Hepatitis B
            • Other Infectious Diseases
          • Genetic testing
            • Newborn screening
            • Predictive and presymptomatic testing
            • Others
          • Neurological disease
          • Cardiovascular disease
          • Microbiology
          • Others
    • Asia Pacific
      • Asia Pacific Molecular Diagnostics Market, By Product
        • Instruments
        • Regards
        • Others
      • Asia Pacific Molecular Diagnostics Market, By Test Location
        • Point of care
        • Self test or OTC
        • Central laboratories
      • Asia Pacific Molecular Diagnostics Market, By Technology
        • Polymerase chain reaction (PCR)
          • PCR, by Procedure
            • Nucleic Acid Extraction
            • Others
          • PCR, by Type
            • Multiplex PCR
            • Other PCR
          • PCR, by Product
            • Instruments
            • Reagents
            • Others
        • In Situ Hybridization (ISH)
          • Instruments
          • Reagents
          • Others
        • Isothermal Nucleic Acid Amplification Technology (INAAT)
          • Instruments
          • Reagents
          • Others
        • Chips and Microarrays
          • Instruments
          • Reagents
          • Others
        • Mass Spectrometry
          • Instruments
          • Reagents
          • Others
        • Transcription Mediated Amplification (TMA)
          • Instruments
          • Reagents
          • Others
        • Others
          • Instruments
          • Reagents
          • Others
      • Asia Pacific Molecular Diagnostics Market, By Application
        • Oncology
          • Breast Cancer
          • Prostate Cancer
          • Colorectal Cancer
          • Cervical
          • Kidney
          • Liver
          • Blood
          • Lung
          • Other
        • Pharmacogenomics
        • Infectious disease
          • MRSA
          • Clostridium difficile
          • Vancomycin-resistant enterococci
          • Carbapenem-resistant bacteria testing
          • Flu
          • Respiratory syncytial virus (RSV)
          • Candida
          • Tuberculosis and drug-resistant TB
          • Meningitis
          • Gastro-intestinal panel testing
          • Chlamydia
          • Gonorrhea
          • HIV
          • Hepatitis C
          • Hepatitis B
          • Other Infectious Diseases
        • Genetic testing
          • Newborn screening
          • Predictive and presymptomatic testing
          • Others
        • Neurological disease
        • Cardiovascular disease
        • Microbiology
        • Others
      • China
        • China Molecular Diagnostics Market, By Product
          • Instruments
          • Regards
          • Others
        • China Molecular Diagnostics Market, By Test Location
          • Point of care
          • Self test or OTC
          • Central laboratories
        • China Molecular Diagnostics Market, By Technology
          • Polymerase chain reaction (PCR)
            • PCR, by Procedure
              • Nucleic Acid Extraction
              • Others
            • PCR, by Type
              • Multiplex PCR
              • Other PCR
            • PCR, by Product
              • Instruments
              • Reagents
              • Others
          • In Situ Hybridization (ISH)
            • Instruments
            • Reagents
            • Others
          • Isothermal Nucleic Acid Amplification Technology (INAAT)
            • Instruments
            • Reagents
            • Others
          • Chips and Microarrays
            • Instruments
            • Reagents
            • Others
          • Mass Spectrometry
            • Instruments
            • Reagents
            • Others
          • Transcription Mediated Amplification (TMA)
            • Instruments
            • Reagents
            • Others
          • Others
            • Instruments
            • Reagents
            • Others
        • China Molecular Diagnostics Market, By Application
          • Oncology
            • Breast Cancer
            • Prostate Cancer
            • Colorectal Cancer
            • Cervical
            • Kidney
            • Liver
            • Blood
            • Lung
            • Other
          • Pharmacogenomics
          • Infectious disease
            • MRSA
            • Clostridium difficile
            • Vancomycin-resistant enterococci
            • Carbapenem-resistant bacteria testing
            • Flu
            • Respiratory syncytial virus (RSV)
            • Candida
            • Tuberculosis and drug-resistant TB
            • Meningitis
            • Gastro-intestinal panel testing
            • Chlamydia
            • Gonorrhea
            • HIV
            • Hepatitis C
            • Hepatitis B
            • Other Infectious Diseases
          • Genetic testing
            • Newborn screening
            • Predictive and presymptomatic testing
            • Others
          • Neurological disease
          • Cardiovascular disease
          • Microbiology
          • Others
      • Japan
        • Japan Molecular Diagnostics Market, By Product
          • Instruments
          • Regards
          • Others
        • Japan Molecular Diagnostics Market, By Test Location
          • Point of care
          • Self test or OTC
          • Central laboratories
        • Japan Molecular Diagnostics Market, By Technology
          • Polymerase chain reaction (PCR)
            • PCR, by Procedure
              • Nucleic Acid Extraction
              • Others
            • PCR, by Type
              • Multiplex PCR
              • Other PCR
            • PCR, by Product
              • Instruments
              • Reagents
              • Others
          • In Situ Hybridization (ISH)
            • Instruments
            • Reagents
            • Others
          • Isothermal Nucleic Acid Amplification Technology (INAAT)
            • Instruments
            • Reagents
            • Others
          • Chips and Microarrays
            • Instruments
            • Reagents
            • Others
          • Mass Spectrometry
            • Instruments
            • Reagents
            • Others
          • Transcription Mediated Amplification (TMA)
            • Instruments
            • Reagents
            • Others
          • Others
            • Instruments
            • Reagents
            • Others
        • Japan Molecular Diagnostics Market, By Application
          • Oncology
            • Breast Cancer
            • Prostate Cancer
            • Colorectal Cancer
            • Cervical
            • Kidney
            • Liver
            • Blood
            • Lung
            • Other
          • Pharmacogenomics
          • Infectious disease
            • MRSA
            • Clostridium difficile
            • Vancomycin-resistant enterococci
            • Carbapenem-resistant bacteria testing
            • Flu
            • Respiratory syncytial virus (RSV)
            • Candida
            • Tuberculosis and drug-resistant TB
            • Meningitis
            • Gastro-intestinal panel testing
            • Chlamydia
            • Gonorrhea
            • HIV
            • Hepatitis C
            • Hepatitis B
            • Other Infectious Diseases
          • Genetic testing
            • Newborn screening
            • Predictive and presymptomatic testing
            • Others
          • Neurological disease
          • Cardiovascular disease
          • Microbiology
          • Others
      • India
        • India Molecular Diagnostics Market, By Product
          • Instruments
          • Regards
          • Others
        • India Molecular Diagnostics Market, By Test Location
          • Point of care
          • Self test or OTC
          • Central laboratories
        • India Molecular Diagnostics Market, By Technology
          • Polymerase chain reaction (PCR)
            • PCR, by Procedure
              • Nucleic Acid Extraction
              • Others
            • PCR, by Type
              • Multiplex PCR
              • Other PCR
            • PCR, by Product
              • Instruments
              • Reagents
              • Others
          • In Situ Hybridization (ISH)
            • Instruments
            • Reagents
            • Others
          • Isothermal Nucleic Acid Amplification Technology (INAAT)
            • Instruments
            • Reagents
            • Others
          • Chips and Microarrays
            • Instruments
            • Reagents
            • Others
          • Mass Spectrometry
            • Instruments
            • Reagents
            • Others
          • Transcription Mediated Amplification (TMA)
            • Instruments
            • Reagents
            • Others
          • Others
            • Instruments
            • Reagents
            • Others
        • India Molecular Diagnostics Market, By Application
          • Oncology
            • Breast Cancer
            • Prostate Cancer
            • Colorectal Cancer
            • Cervical
            • Kidney
            • Liver
            • Blood
            • Lung
            • Other
          • Pharmacogenomics
          • Infectious disease
            • MRSA
            • Clostridium difficile
            • Vancomycin-resistant enterococci
            • Carbapenem-resistant bacteria testing
            • Flu
            • Respiratory syncytial virus (RSV)
            • Candida
            • Tuberculosis and drug-resistant TB
            • Meningitis
            • Gastro-intestinal panel testing
            • Chlamydia
            • Gonorrhea
            • HIV
            • Hepatitis C
            • Hepatitis B
            • Other Infectious Diseases
          • Genetic testing
            • Newborn screening
            • Predictive and presymptomatic testing
            • Others
          • Neurological disease
          • Cardiovascular disease
          • Microbiology
          • Others
      • South Korea
        • South Korea Molecular Diagnostics Market, By Product
          • Instruments
          • Regards
          • Others
        • South Korea Molecular Diagnostics Market, By Test Location
          • Point of care
          • Self test or OTC
          • Central laboratories
        • South Korea Molecular Diagnostics Market, By Technology
          • Polymerase chain reaction (PCR)
            • PCR, by Procedure
              • Nucleic Acid Extraction
              • Others
            • PCR, by Type
              • Multiplex PCR
              • Other PCR
            • PCR, by Product
              • Instruments
              • Reagents
              • Others
          • In Situ Hybridization (ISH)
            • Instruments
            • Reagents
            • Others
          • Isothermal Nucleic Acid Amplification Technology (INAAT)
            • Instruments
            • Reagents
            • Others
          • Chips and Microarrays
            • Instruments
            • Reagents
            • Others
          • Mass Spectrometry
            • Instruments
            • Reagents
            • Others
          • Transcription Mediated Amplification (TMA)
            • Instruments
            • Reagents
            • Others
          • Others
            • Instruments
            • Reagents
            • Others
        • South Korea Molecular Diagnostics Market, By Application
          • Oncology
            • Breast Cancer
            • Prostate Cancer
            • Colorectal Cancer
            • Cervical
            • Kidney
            • Liver
            • Blood
            • Lung
            • Other
          • Pharmacogenomics
          • Infectious disease
            • MRSA
            • Clostridium difficile
            • Vancomycin-resistant enterococci
            • Carbapenem-resistant bacteria testing
            • Flu
            • Respiratory syncytial virus (RSV)
            • Candida
            • Tuberculosis and drug-resistant TB
            • Meningitis
            • Gastro-intestinal panel testing
            • Chlamydia
            • Gonorrhea
            • HIV
            • Hepatitis C
            • Hepatitis B
            • Other Infectious Diseases
          • Genetic testing
            • Newborn screening
            • Predictive and presymptomatic testing
            • Others
          • Neurological disease
          • Cardiovascular disease
          • Microbiology
          • Others
      • Australia
        • Australia Molecular Diagnostics Market, By Product
          • Instruments
          • Regards
          • Others
        • Australia Molecular Diagnostics Market, By Test Location
          • Point of care
          • Self test or OTC
          • Central laboratories
        • Australia Molecular Diagnostics Market, By Technology
          • Polymerase chain reaction (PCR)
            • PCR, by Procedure
              • Nucleic Acid Extraction
              • Others
            • PCR, by Type
              • Multiplex PCR
              • Other PCR
            • PCR, by Product
              • Instruments
              • Reagents
              • Others
          • In Situ Hybridization (ISH)
            • Instruments
            • Reagents
            • Others
          • Isothermal Nucleic Acid Amplification Technology (INAAT)
            • Instruments
            • Reagents
            • Others
          • Chips and Microarrays
            • Instruments
            • Reagents
            • Others
          • Mass Spectrometry
            • Instruments
            • Reagents
            • Others
          • Transcription Mediated Amplification (TMA)
            • Instruments
            • Reagents
            • Others
          • Others
            • Instruments
            • Reagents
            • Others
        • Australia Molecular Diagnostics Market, By Application
          • Oncology
            • Breast Cancer
            • Prostate Cancer
            • Colorectal Cancer
            • Cervical
            • Kidney
            • Liver
            • Blood
            • Lung
            • Other
          • Pharmacogenomics
          • Infectious disease
            • MRSA
            • Clostridium difficile
            • Vancomycin-resistant enterococci
            • Carbapenem-resistant bacteria testing
            • Flu
            • Respiratory syncytial virus (RSV)
            • Candida
            • Tuberculosis and drug-resistant TB
            • Meningitis
            • Gastro-intestinal panel testing
            • Chlamydia
            • Gonorrhea
            • HIV
            • Hepatitis C
            • Hepatitis B
            • Other Infectious Diseases
          • Genetic testing
            • Newborn screening
            • Predictive and presymptomatic testing
            • Others
          • Neurological disease
          • Cardiovascular disease
          • Microbiology
          • Others
      • Thailand
        • Thailand Molecular Diagnostics Market, By Product
          • Instruments
          • Regards
          • Others
        • Thailand Molecular Diagnostics Market, By Test Location
          • Point of care
          • Self test or OTC
          • Central laboratories
        • Thailand Molecular Diagnostics Market, By Technology
          • Polymerase chain reaction (PCR)
            • PCR, by Procedure
              • Nucleic Acid Extraction
              • Others
            • PCR, by Type
              • Multiplex PCR
              • Other PCR
            • PCR, by Product
              • Instruments
              • Reagents
              • Others
          • In Situ Hybridization (ISH)
            • Instruments
            • Reagents
            • Others
          • Isothermal Nucleic Acid Amplification Technology (INAAT)
            • Instruments
            • Reagents
            • Others
          • Chips and Microarrays
            • Instruments
            • Reagents
            • Others
          • Mass Spectrometry
            • Instruments
            • Reagents
            • Others
          • Transcription Mediated Amplification (TMA)
            • Instruments
            • Reagents
            • Others
          • Others
            • Instruments
            • Reagents
            • Others
        • Thailand Molecular Diagnostics Market, By Application
          • Oncology
            • Breast Cancer
            • Prostate Cancer
            • Colorectal Cancer
            • Cervical
            • Kidney
            • Liver
            • Blood
            • Lung
            • Other
          • Pharmacogenomics
          • Infectious disease
            • MRSA
            • Clostridium difficile
            • Vancomycin-resistant enterococci
            • Carbapenem-resistant bacteria testing
            • Flu
            • Respiratory syncytial virus (RSV)
            • Candida
            • Tuberculosis and drug-resistant TB
            • Meningitis
            • Gastro-intestinal panel testing
            • Chlamydia
            • Gonorrhea
            • HIV
            • Hepatitis C
            • Hepatitis B
            • Other Infectious Diseases
          • Genetic testing
            • Newborn screening
            • Predictive and presymptomatic testing
            • Others
          • Neurological disease
          • Cardiovascular disease
          • Microbiology
          • Others
    • Latin America
      • Latin America Molecular Diagnostics Market, By Product
        • Instruments
        • Regards
        • Others
      • Latin America Molecular Diagnostics Market, By Test Location
        • Point of care
        • Self test or OTC
        • Central laboratories
      • Latin America Molecular Diagnostics Market, By Technology
        • Polymerase chain reaction (PCR)
          • PCR, by Procedure
            • Nucleic Acid Extraction
            • Others
          • PCR, by Type
            • Multiplex PCR
            • Other PCR
          • PCR, by Product
            • Instruments
            • Reagents
            • Others
        • In Situ Hybridization (ISH)
          • Instruments
          • Reagents
          • Others
        • Isothermal Nucleic Acid Amplification Technology (INAAT)
          • Instruments
          • Reagents
          • Others
        • Chips and Microarrays
          • Instruments
          • Reagents
          • Others
        • Mass Spectrometry
          • Instruments
          • Reagents
          • Others
        • Transcription Mediated Amplification (TMA)
          • Instruments
          • Reagents
          • Others
        • Others
          • Instruments
          • Reagents
          • Others
      • Latin America Molecular Diagnostics Market, By Application
        • Oncology
          • Breast Cancer
          • Prostate Cancer
          • Colorectal Cancer
          • Cervical
          • Kidney
          • Liver
          • Blood
          • Lung
          • Other
        • Pharmacogenomics
        • Infectious disease
          • MRSA
          • Clostridium difficile
          • Vancomycin-resistant enterococci
          • Carbapenem-resistant bacteria testing
          • Flu
          • Respiratory syncytial virus (RSV)
          • Candida
          • Tuberculosis and drug-resistant TB
          • Meningitis
          • Gastro-intestinal panel testing
          • Chlamydia
          • Gonorrhea
          • HIV
          • Hepatitis C
          • Hepatitis B
          • Other Infectious Diseases
        • Genetic testing
          • Newborn screening
          • Predictive and presymptomatic testing
          • Others
        • Neurological disease
        • Cardiovascular disease
        • Microbiology
        • Others
      • Brazil
        • Brazil Molecular Diagnostics Market, By Product
          • Instruments
          • Regards
          • Others
        • Brazil Molecular Diagnostics Market, By Test Location
          • Point of care
          • Self test or OTC
          • Central laboratories
        • Brazil Molecular Diagnostics Market, By Technology
          • Polymerase chain reaction (PCR)
            • PCR, by Procedure
              • Nucleic Acid Extraction
              • Others
            • PCR, by Type
              • Multiplex PCR
              • Other PCR
            • PCR, by Product
              • Instruments
              • Reagents
              • Others
          • In Situ Hybridization (ISH)
            • Instruments
            • Reagents
            • Others
          • Isothermal Nucleic Acid Amplification Technology (INAAT)
            • Instruments
            • Reagents
            • Others
          • Chips and Microarrays
            • Instruments
            • Reagents
            • Others
          • Mass Spectrometry
            • Instruments
            • Reagents
            • Others
          • Transcription Mediated Amplification (TMA)
            • Instruments
            • Reagents
            • Others
          • Others
            • Instruments
            • Reagents
            • Others
        • Brazil Molecular Diagnostics Market, By Application
          • Oncology
            • Breast Cancer
            • Prostate Cancer
            • Colorectal Cancer
            • Cervical
            • Kidney
            • Liver
            • Blood
            • Lung
            • Other
          • Pharmacogenomics
          • Infectious disease
            • MRSA
            • Clostridium difficile
            • Vancomycin-resistant enterococci
            • Carbapenem-resistant bacteria testing
            • Flu
            • Respiratory syncytial virus (RSV)
            • Candida
            • Tuberculosis and drug-resistant TB
            • Meningitis
            • Gastro-intestinal panel testing
            • Chlamydia
            • Gonorrhea
            • HIV
            • Hepatitis C
            • Hepatitis B
            • Other Infectious Diseases
          • Genetic testing
            • Newborn screening
            • Predictive and presymptomatic testing
            • Others
          • Neurological disease
          • Cardiovascular disease
          • Microbiology
          • Others
      • Argentina
        • Argentina Molecular Diagnostics Market, By Product
          • Instruments
          • Regards
          • Others
        • Argentina Molecular Diagnostics Market, By Test Location
          • Point of care
          • Self test or OTC
          • Central laboratories
        • Argentina Molecular Diagnostics Market, By Technology
          • Polymerase chain reaction (PCR)
            • PCR, by Procedure
              • Nucleic Acid Extraction
              • Others
            • PCR, by Type
              • Multiplex PCR
              • Other PCR
            • PCR, by Product
              • Instruments
              • Reagents
              • Others
          • In Situ Hybridization (ISH)
            • Instruments
            • Reagents
            • Others
          • Isothermal Nucleic Acid Amplification Technology (INAAT)
            • Instruments
            • Reagents
            • Others
          • Chips and Microarrays
            • Instruments
            • Reagents
            • Others
          • Mass Spectrometry
            • Instruments
            • Reagents
            • Others
          • Transcription Mediated Amplification (TMA)
            • Instruments
            • Reagents
            • Others
          • Others
            • Instruments
            • Reagents
            • Others
        • Argentina Molecular Diagnostics Market, By Application
          • Oncology
            • Breast Cancer
            • Prostate Cancer
            • Colorectal Cancer
            • Cervical
            • Kidney
            • Liver
            • Blood
            • Lung
            • Other
          • Pharmacogenomics
          • Infectious disease
            • MRSA
            • Clostridium difficile
            • Vancomycin-resistant enterococci
            • Carbapenem-resistant bacteria testing
            • Flu
            • Respiratory syncytial virus (RSV)
            • Candida
            • Tuberculosis and drug-resistant TB
            • Meningitis
            • Gastro-intestinal panel testing
            • Chlamydia
            • Gonorrhea
            • HIV
            • Hepatitis C
            • Hepatitis B
            • Other Infectious Diseases
          • Genetic testing
            • Newborn screening
            • Predictive and presymptomatic testing
            • Others
          • Neurological disease
          • Cardiovascular disease
          • Microbiology
          • Others
    • Middle East and Africa (MEA)
      • Middle East and Africa (MEA) Molecular Diagnostics Market, By Product
        • Instruments
        • Reagents
        • Others
      • Middle East and Africa (MEA) Molecular Diagnostics Market, By Test Location
        • Point of care
        • Self test or OTC
        • Central laboratories
      • Middle East and Africa (MEA) Molecular Diagnostics Market, By Technology
        • Polymerase chain reaction (PCR)
          • PCR, by Procedure
            • Nucleic Acid Extraction
            • Others
          • PCR, by Type
            • Multiplex PCR
            • Other PCR
          • PCR, by Product
            • Instruments
            • Reagents
            • Others
        • In Situ Hybridization (ISH)
          • Instruments
          • Reagents
          • Others
        • Isothermal Nucleic Acid Amplification Technology (INAAT)
          • Instruments
          • Reagents
          • Others
        • Chips and Microarrays
          • Instruments
          • Reagents
          • Others
        • Mass Spectrometry
          • Instruments
          • Reagents
          • Others
        • Transcription Mediated Amplification (TMA)
          • Instruments
          • Reagents
          • Others
        • Others
          • Instruments
          • Reagents
          • Others
      • Middle East and Africa (MEA) Molecular Diagnostics Market, By Application
        • Oncology
          • Breast Cancer
          • Prostate Cancer
          • Colorectal Cancer
          • Cervical
          • Kidney
          • Liver
          • Blood
          • Lung
          • Other
        • Pharmacogenomics
        • Infectious disease
          • MRSA
          • Clostridium difficile
          • Vancomycin-resistant enterococci
          • Carbapenem-resistant bacteria testing
          • Flu
          • Respiratory syncytial virus (RSV)
          • Candida
          • Tuberculosis and drug-resistant TB
          • Meningitis
          • Gastro-intestinal panel testing
          • Chlamydia
          • Gonorrhea
          • HIV
          • Hepatitis C
          • Hepatitis B
          • Other Infectious Diseases
        • Genetic testing
          • Newborn screening
          • Predictive and presymptomatic testing
          • Others
        • Neurological disease
        • Cardiovascular disease
        • Microbiology
        • Others
      • South Africa
        • South Africa Molecular Diagnostics Market, By Product
          • Instruments
          • Reagents
          • Others
        • South Africa Molecular Diagnostics Market, By Test Location
          • Point of care
          • Self test or OTC
          • Central laboratories
        • South Africa Molecular Diagnostics Market, By Technology
          • Polymerase chain reaction (PCR)
            • PCR, by Procedure
              • Nucleic Acid Extraction
              • Others
            • PCR, by Type
              • Multiplex PCR
              • Other PCR
            • PCR, by Product
              • Instruments
              • Reagents
              • Others
          • In Situ Hybridization (ISH)
            • Instruments
            • Reagents
            • Others
          • Isothermal Nucleic Acid Amplification Technology (INAAT)
            • Instruments
            • Reagents
            • Others
          • Chips and Microarrays
            • Instruments
            • Reagents
            • Others
          • Mass Spectrometry
            • Instruments
            • Reagents
            • Others
          • Transcription Mediated Amplification (TMA)
            • Instruments
            • Reagents
            • Others
          • Others
            • Instruments
            • Reagents
            • Others
        • South Africa Molecular Diagnostics Market, By Application
          • Oncology
            • Breast Cancer
            • Prostate Cancer
            • Colorectal Cancer
            • Cervical
            • Kidney
            • Liver
            • Blood
            • Lung
            • Other
          • Pharmacogenomics
          • Infectious disease
            • MRSA
            • Clostridium difficile
            • Vancomycin-resistant enterococci
            • Carbapenem-resistant bacteria testing
            • Flu
            • Respiratory syncytial virus (RSV)
            • Candida
            • Tuberculosis and drug-resistant TB
            • Meningitis
            • Gastro-intestinal panel testing
            • Chlamydia
            • Gonorrhea
            • HIV
            • Hepatitis C
            • Hepatitis B
            • Other Infectious Diseases
          • Genetic testing
            • Newborn screening
            • Predictive and presymptomatic testing
            • Others
          • Neurological disease
          • Cardiovascular disease
          • Microbiology
          • Others
      • Saudi Arabia
        • Saudi Arabia Molecular Diagnostics Market, By Product
          • Instruments
          • Reagents
          • Others
        • Saudi Arabia Molecular Diagnostics Market, By Test Location
          • Point of care
          • Self test or OTC
          • Central laboratories
        • Saudi Arabia Molecular Diagnostics Market, By Technology
          • Polymerase chain reaction (PCR)
            • PCR, by Procedure
              • Nucleic Acid Extraction
              • Others
            • PCR, by Type
              • Multiplex PCR
              • Other PCR
            • PCR, by Product
              • Instruments
              • Reagents
              • Others
          • In Situ Hybridization (ISH)
            • Instruments
            • Reagents
            • Others
          • Isothermal Nucleic Acid Amplification Technology (INAAT)
            • Instruments
            • Reagents
            • Others
          • Chips and Microarrays
            • Instruments
            • Reagents
            • Others
          • Mass Spectrometry
            • Instruments
            • Reagents
            • Others
          • Transcription Mediated Amplification (TMA)
            • Instruments
            • Reagents
            • Others
          • Others
            • Instruments
            • Reagents
            • Others
        • Saudi Arabia Molecular Diagnostics Market, By Application
          • Oncology
            • Breast Cancer
            • Prostate Cancer
            • Colorectal Cancer
            • Cervical
            • Kidney
            • Liver
            • Blood
            • Lung
            • Other
          • Pharmacogenomics
          • Infectious disease
            • MRSA
            • Clostridium difficile
            • Vancomycin-resistant enterococci
            • Carbapenem-resistant bacteria testing
            • Flu
            • Respiratory syncytial virus (RSV)
            • Candida
            • Tuberculosis and drug-resistant TB
            • Meningitis
            • Gastro-intestinal panel testing
            • Chlamydia
            • Gonorrhea
            • HIV
            • Hepatitis C
            • Hepatitis B
            • Other Infectious Diseases
          • Genetic testing
            • Newborn screening
            • Predictive and presymptomatic testing
            • Others
          • Neurological disease
          • Cardiovascular disease
          • Microbiology
          • Others
      • UAE
        • UAE Molecular Diagnostics Market, By Product
          • Instruments
          • Reagents
          • Others
        • UAE Molecular Diagnostics Market, By Test Location
          • Point of care
          • Self test or OTC
          • Central laboratories
        • UAE Molecular Diagnostics Market, By Technology
          • Polymerase chain reaction (PCR)
            • PCR, by Procedure
              • Nucleic Acid Extraction
              • Others
            • PCR, by Type
              • Multiplex PCR
              • Other PCR
            • PCR, by Product
              • Instruments
              • Reagents
              • Others
          • In Situ Hybridization (ISH)
            • Instruments
            • Reagents
            • Others
          • Isothermal Nucleic Acid Amplification Technology (INAAT)
            • Instruments
            • Reagents
            • Others
          • Chips and Microarrays
            • Instruments
            • Reagents
            • Others
          • Mass Spectrometry
            • Instruments
            • Reagents
            • Others
          • Transcription Mediated Amplification (TMA)
            • Instruments
            • Reagents
            • Others
          • Others
            • Instruments
            • Reagents
            • Others
        • UAE Molecular Diagnostics Market, By Application
          • Oncology
            • Breast Cancer
            • Prostate Cancer
            • Colorectal Cancer
            • Cervical
            • Kidney
            • Liver
            • Blood
            • Lung
            • Other
          • Pharmacogenomics
          • Infectious disease
            • MRSA
            • Clostridium difficile
            • Vancomycin-resistant enterococci
            • Carbapenem-resistant bacteria testing
            • Flu
            • Respiratory syncytial virus (RSV)
            • Candida
            • Tuberculosis and drug-resistant TB
            • Meningitis
            • Gastro-intestinal panel testing
            • Chlamydia
            • Gonorrhea
            • HIV
            • Hepatitis C
            • Hepatitis B
            • Other Infectious Diseases
          • Genetic testing
            • Newborn screening
            • Predictive and presymptomatic testing
            • Others
          • Neurological disease
          • Cardiovascular disease
          • Microbiology
          • Others
      • Kuwait
        • Kuwait Molecular Diagnostics Market, By Product
          • Instruments
          • Reagents
          • Others
        • Kuwait Molecular Diagnostics Market, By Test Location
          • Point of care
          • Self test or OTC
          • Central laboratories
        • Kuwait Molecular Diagnostics Market, By Technology
          • Polymerase chain reaction (PCR)
            • PCR, by Procedure
              • Nucleic Acid Extraction
              • Others
            • PCR, by Type
              • Multiplex PCR
              • Other PCR
            • PCR, by Product
              • Instruments
              • Reagents
              • Others
          • In Situ Hybridization (ISH)
            • Instruments
            • Reagents
            • Others
          • Isothermal Nucleic Acid Amplification Technology (INAAT)
            • Instruments
            • Reagents
            • Others
          • Chips and Microarrays
            • Instruments
            • Reagents
            • Others
          • Mass Spectrometry
            • Instruments
            • Reagents
            • Others
          • Transcription Mediated Amplification (TMA)
            • Instruments
            • Reagents
            • Others
          • Others
            • Instruments
            • Reagents
            • Others
        • Kuwait Molecular Diagnostics Market, By Application
          • Oncology
            • Breast Cancer
            • Prostate Cancer
            • Colorectal Cancer
            • Cervical
            • Kidney
            • Liver
            • Blood
            • Lung
            • Other
          • Pharmacogenomics
          • Infectious disease
            • MRSA
            • Clostridium difficile
            • Vancomycin-resistant enterococci
            • Carbapenem-resistant bacteria testing
            • Flu
            • Respiratory syncytial virus (RSV)
            • Candida
            • Tuberculosis and drug-resistant TB
            • Meningitis
            • Gastro-intestinal panel testing
            • Chlamydia
            • Gonorrhea
            • HIV
            • Hepatitis C
            • Hepatitis B
            • Other Infectious Diseases
          • Genetic testing
            • Newborn screening
            • Predictive and presymptomatic testing
            • Others
          • Neurological disease
          • Cardiovascular disease
          • Microbiology
          • Others

Report content

Qualitative Analysis

  • Industry overview
  • Industry trends
  • Market drivers and restraints
  • Market size
  • Growth prospects
  • Porter’s analysis
  • PESTEL analysis
  • Key market opportunities prioritized
  • Competitive landscape
    • Company overview
    • Financial performance
    • Product benchmarking
    • Latest strategic developments

Quantitative Analysis

  • Market size, estimates, and forecast from 2018 to 2030
  • Market estimates and forecast for product segments up to 2030
  • Regional market size and forecast for product segments up to 2030
  • Market estimates and forecast for application segments up to 2030
  • Regional market size and forecast for application segments up to 2030
  • Company financial performance
What questions do you have? Get quick response from our industry experts. Request a Free Consultation

Research Methodology

Grand View Research employs a comprehensive and iterative research methodology focused on minimizing deviance in order to provide the most accurate estimates and forecast possible. The company utilizes a combination of bottom-up and top-down approaches for segmenting and estimating quantitative aspects of the market. In Addition, a recurring theme prevalent across all our research reports is data triangulation that looks market from three different perspectives. Critical elements of the methodology employed for all our studies include:

Preliminary data mining

Raw market data is obtained and collated on a broad front. Data is continuously filtered to ensure that only validated and authenticated sources are considered. In addition, data is also mined from a host of reports in our repository, as well as a number of reputed paid databases. For a comprehensive understanding of the market, it is essential to understand the complete value chain, and in order to facilitate this; we collect data from raw material suppliers, distributors as well as buyers.

Technical issues and trends are obtained from surveys, technical symposia, and trade journals. Technical data is also gathered from an intellectual property perspective, focusing on white space and freedom of movement. Industry dynamics with respect to drivers, restraints, pricing trends are also gathered. As a result, the material developed contains a wide range of original data that is then further cross-validated and authenticated with published sources.

Statistical model

Our market estimates and forecasts are derived through simulation models. A unique model is created customized for each study. Gathered information for market dynamics, technology landscape, application development, and pricing trends are fed into the model and analyzed simultaneously. These factors are studied on a comparative basis, and their impact over the forecast period is quantified with the help of correlation, regression, and time series analysis. Market forecasting is performed via a combination of economic tools, technological analysis, industry experience, and domain expertise.

Econometric models are generally used for short-term forecasting, while technological market models are used for long-term forecasting. These are based on an amalgamation of the technology landscape, regulatory frameworks, economic outlook, and business principles. A bottom-up approach to market estimation is preferred, with key regional markets analyzed as separate entities and integration of data to obtain global estimates. This is critical for a deep understanding of the industry as well as ensuring minimal errors. Some of the parameters considered for forecasting include:

    • Market drivers and restraints, along with their current and expected impact
    • Raw material scenario and supply v/s price trends
    • Regulatory scenario and expected developments
    • Current capacity and expected capacity additions up to 2030

We assign weights to these parameters and quantify their market impact using weighted average analysis, to derive an expected market growth rate.

Primary validation

This is the final step in estimating and forecasting for our reports. Exhaustive primary interviews are conducted, face to face as well as over the phone to validate our findings and assumptions used to obtain them. Interviewees are approached from leading companies across the value chain including suppliers, technology providers, domain experts, and buyers so as to ensure a holistic and unbiased picture of the market. These interviews are conducted across the globe, with language barriers overcome with the aid of local staff and interpreters. Primary interviews not only help in data validation but also provide critical insights into the market, current business scenario, and future expectations and enhance the quality of our reports. All our estimates and forecast are verified through exhaustive primary research with Key Industry Participants (KIPs) which typically include:

    • Market-leading companies
    • Raw material suppliers
    • Product distributors
    • Buyers

The key objectives of primary research are as follows:

    • To validate our data in terms of accuracy and acceptability
    • To gain an insight in to the current market and future expectations

Data Collection Matrix

Perspective

Primary research

Secondary research

Supply-side
  • Manufacturers
  • Technology distributors and wholesalers
  • Company reports and publications
  • Government publications
  • Independent investigations
  • Economic and demographic data

Demand-side
  • End-user surveys
  • Consumer surveys
  • Mystery shopping
  • Case studies
  • Reference customers


Industry Analysis Matrix

Qualitative analysis

Quantitative analysis
  • Industry landscape and trends
  • Market dynamics and key issues
  • Technology landscape
  • Market opportunities
  • Porter’s analysis and PESTEL analysis
  • Competitive landscape and component benchmarking
  • Policy and regulatory scenario
  • Market revenue estimates and forecast up to 2030
  • Market revenue estimates and forecasts up to 2030, by technology
  • Market revenue estimates and forecasts up to 2030, by application
  • Market revenue estimates and forecasts up to 2030, by type
  • Market revenue estimates and forecasts up to 2030, by component
  • Regional market revenue forecasts, by technology
  • Regional market revenue forecasts, by application
  • Regional market revenue forecasts, by type
  • Regional market revenue forecasts, by component

 

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
Jump to content
pdf icn

GET A FREE SAMPLE

arrow icn

This FREE sample includes data points, ranging from trend analyses to estimates and forecasts. See for yourself.

Or view our licence options:

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now

Certified Icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.